This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Mackowiak PA: The normal microbial flora. N Engl J Med 307: 83–93, 1982.
Abraham SN: Host defenses against adhesion of bacteria to mucosal surfaces. In Gallin JI, Fauci AS (eds): Advances in Host Defense Mechanisms, Vol. 4. Raven Press, New York, 1985, pp. 63–88.
Savage DC: Colonization by and survival of pathogenic bacteria on intestinal mucosal surfaces. In Britton G, Marschall KC (eds): Adsorption of Microorganisms to Surfaces. John Wiley, New York, 1980, pp. 175–206.
Guiot HF: Role of competition for substrate in bacterial antagonism in the gut. Infect Immun 38:887–892, 1982.
Van der Waay D, Berghuis-de Vries JM, Lekkerkerk-van der Wees JEC: Colonization resistance of the digestive tract and the spread of bacteria to the lymphatic organs in mice. J Hyg 70:335–342, 1972.
Heczko PB, Pryjma J, Kasprowicz J: Influence of host and parasite factors on the nasal carriage of staphylococci. In Jeljaszawicz J (ed): Staphylococci and Staphylococcal Infection. Karger, Basel, 1973, pp. 581–594.
Young LS, LaForce FM, Head JJ, Feeley JC, Bennett JV: A simultaneous outbreak of meningococcal and influenza infections. N Engl J Med 287:5–9, 1972.
Sanford BA, Shelokov A, Ramsay MA: Bacterial adherence to irus-infected cells: A cell culture model of bacterial superinfection. J Infect Dis 137:176–181, 1978.
Kominos SD, Copeland CE, Grosiak B, Postic B: Introduction of Pseudomonas aeruginosa into a hospital via vegetables. Appl Microbiol 24:567–570, 1972.
Pollack M, Charache P, Nieman RE, Jett MP, Reimhardt JA, Hardy PH Jr: Factors influencing colonisation and antibiotic-resistance patterns of gram-negative bacteria in hospital patients. Lancet 2:668–671, 1972.
Beachey EH: Bacterial adherence: Adhesin-receptor interactions mediating the attachment of bacteria to mucosal surface. J Infect Dis 143:325–345, 1981.
Johnson JR: Virulence factors in Escherichia coli urinary tract infection. Clin Microbiol Rev 4:80–128, 1991.
Kinsman OS, McKenna R, Noble WC: Association between histocompatability antigens (HLA) and nasal carriage of Staphylococcus aureus. J Med Microbiol 16:215–220, 1983.
Noble WC: Carriage of Staphylococcus aureus and beta haemolytic streptococci in relation to race. Acta Derm Venereol 54:403–405, 1974.
Winkler J, Block C, Leibovici L, Faktor J, Pitlik SD: Nasal carriage of Staphylococcus aureus: Correlation with hormonal status in women. J Infect Dis 162:1400–1402, 1990.
Thadepalli H, Chan WH, Maidman JE, Davidson EC Jr: Microflora of the cervix during normal labor and the puerperium. J Infect Dis 137:568–572, 1978.
Mackowiak PA, Martin RM, Smith JW: The role of bacterial interference in the increased prevalence of oropharyngeal gramnegative bacilli among alcoholics and diabetics. Am Rev Respir Dis 120:589–593, 1979.
Tuazon CU, Sheagren JN: Increased rate of carriage of Staphylococcus aureus among narcotic addicts. J Infect Dis 129:725–727, 1974.
Chow JW, Yu VL: Staphylococcus aureus nasal carriage in hemodialysis patients. Its role in infection and approaches to prophylaxis. Arch Intern Med 149:1258–1262, 1989.
Klein RS, Recco RA, Catalano MT, Edberg SC, Casey JI, Steigbigel NH: Association of Streptococcus bovis with carcinoma of the colon. N Engl J Med 297:800–802, 1977.
Alpern RJ, Dowell VR Jr.: Clostridium seplicum infections and malignancy. JAMA 209:385–388, 1969.
Black PH, Kunz LJ, Swartz MN: Salmonellosis—A review of some unusual aspects. N Engl J Med 262:811–817, 864–870, 921–927, 1960.
Reichert U, Saint Leger D, Schaefffer H: Skin surface chemistry and microbial infection. Semin Dermatol 1:91–100, 1982.
Smith RF: Lactic acid utilization by the cutaneous Micrococcaceae. Appl Microbiol 21:777–779, 1971.
Blank I, Oawes RK: The water content of Stratum corneum: The importance of water in promoting bacterial multiplication on cornified epithelium. J Invest Dermatol 31:141–145, 1958.
Newhouse M, Sanchis J, Bienenstock J: Lung defense mechanisms (first of two parts). N Engl J Med 295:990–998, 1976.
Giannella RA, Broitman SA, Zamcheck N: Influence of gastric acidity on bacterial and parasitic enteric infections. A perspective. Ann Intern Med 78:271–276, 1973.
Binder HJ, Filburn B, Floch M: Bile acid inhibition of intestinal anaerobic organisms. Am J Clin Nutr 28:119–125, 1975.
Hinman F Jr, Cox CE: The voiding vesical defense mechanism: The mathematical effect of residual urine, voiding interval and volume on bacteriuria. J Urol 96:491–498, 1966.
Klebanoff SJ, Hillier SL, Eschenbach DA, Waltersdorph AM: Control of the microbial flora of the vagina by H2O3-generating lactobacilli. J Infect Dis 164:94–100, 1991.
Strominger JL, Tipper DJ: Structure of bacterial cell walls: The lysozyme substrate. In Osserman E, Canfield W (eds): Lysozyme. Academic Press, New York, 1974, pp. 169–184.
Masson PL, Heremans JF, Schonne E: Lactoferrin, an iron-binding protein in neutrophilic leukocytes. J Exp Med 130:643–658, 1969.
McClelland DB, van Furth R: In vitro synthesis of lysozyme by human and mouse tissues and leucocytes. Immunology 28:1099–1114, 1975.
Joiner KA, Brown EJ, Frank MM: Complement and bacteria: Chemistry and biology in host defense. Annu Revlmmunol 2:461–491, 1984.
Daha MR: Biological properties of immune complexes. Neth J Med 27:375–379, 1984.
Figueroa JE, Densen P: Infectious diseases associated with complement deficiencies. Clin Microbiol Rev 4:359–395, 1991.
Alper CA, Colten HR, Gear JS, Rabson AR, Rosen FS: Homozygous human C3 deficiency. The role of C3 in antibody production, C-ls-induced vasopermeability, and cobravenom-induced passive hemolysis. J Clin Invest 57:222–229, 1976.
Roord JJ, Daha M, Kuis W, et al: Inherited deficiency of the third component of complement associated with recurrent pyogenic infections, circulating immune complexes, and vasculitis in a Dutch family. Pediatrics 71:81–87, 1983.
Snyderman R, Durack DT, McCarty GA, Ward FE, Meadows L: Deficiency of the fifth component of complement in human subjects. Clinical, genetic and immunologic studies in a large kindred. Am J Med 67:638–645, 1979.
Miller ME, Koblenzer PJ: Leiner’s disease and deficiency of C5. J Pediatr 80:879–880, 1972.
Ellison RTD, Kohler PF, Curd JG, Judson FN, Reller LB: Prevalence of congenital or acquired complement deficiency in patients with sporadic meningococcal disease. N Engl J Med 308:913–916, 1983.
Newman SL, Vogler LB, Feigin RD, Johnston RB Jr: Recurrent septicemia associated with congenital deficiency of C2 and partial deficiency of factor B and the alternative complement pathway. N Engl J Med 299:290–292, 1978.
Kluin-Nelemans HC, van Velzen-Blad H, van Helden HP, Daha MR: Functional deficiency of complement factor D in a monozygous twin. Clin Exp Immunol 58:724–730, 1984.
Ziegler JB, Alper CA, Rosen RS, Lachmann PJ, Sherington L: Restoration by purified C3b inactivator of complement-mediated function in vivo in a patient with C3b inactivator deficiency. J Clin Invest 55:668–672, 1975.
Johnston RB Jr, Newman SL, Struth AG: An abnormality of the alternate pathway of complement activation in sickle-cell disease. N Engl J Med 288:803–808, 1973.
Hand WL, King NL: Serum opsonization of salmonella in sickle cell anemia. Am J Med 64:388–395, 1978.
Fearon DT, Ruddy S, Schur PH, McCabe WR: Activation of the properdin pathway of complement in patients with gram-negative bacteremia. N Engl J Med 292:937–940, 1975.
Rytel MW, Dee TH, Ferstenfeld JE, Hensley GT: Possible pathogenetic role of capsular antigens in fulminant pneumococcal disease with disseminated intravascular coagulation (DIC). Am J Med 57:889–896, 1974.
Greenwood BM, Onyewotu II, Whittle HC: Complement and meningococcal infection. Br Med J 1:797–799, 1976.
Dance DAB, Smith CL: Complement deficiency and sporadic meningococcal disease. N Engl J Med 309:615–616, 1983.
Lehman TJ, Bernstein B, Hanson V, Kornreich H, King K: Meningococcal infection complicating systemic lupus erythematosus. J Pediatr 99:94–96, 1981.
Breedveld FC, Lafeber GJ, van den Barselaar MT, van Dissel JT, Leijh PC: Phagocytosis and intracellular killing of Staphylococcus aureus by polymorphonuclear cells from synovial fluid of patients with rheumatoid arthritis. Arthritis Rheum 29:166–173, 1986.
Hostetter MK: Handicaps to host defense. Effects of hyperglycemia on C3 and Candida albicans. Diabetes 39:271–275, 1990.
Lachmann PJ: Antibody and complement in viral infections. Br Med Bull 41:3–6, 1985.
Proctor RA: Fibronectin: A brief overview of its structure, function, and physiology. Rev Infect Dis 9(Suppl 4): S317–S321, 1987.
Tamkun JW, Hynes RO: Plasma fibronectin is synlhesized and secreted by hepatocytes. J Biol Chem 258:4641–4647, 1983.
Bevilacqua MP, Amrani D, Mosesson MW, Bianco C: Receptors for cold-insoluble globulin (plasma fibronectin) on human monocyles. J Exp Med 153:42–60, 1981.
Proctor RA: Fibronectin: An enhancer of phagocyte function. Rev Infect Dis 9(Suppl 4):S412–S419, 1987.
Mosher DF, Williams EM: Fibronectin concentration is decreased in plasma of severely ill patients with disseminated inlravascular coagulalion. J Lab Clin Med 91:729–735, 1978.
Grossman JE: Plasma fibroneclin and fibronectin therapy in sepsis and critical illness. Rev Infect Dis 9(Suppl 4):S420–S430, 1987.
Shirakami A, Shigekiyo T, Hirai Y, et al: Plasma fibronectin deficiency in eightmembers of one family. Lancet 1:473–474, 1986.
Balkwill FR: Interferons. Lancet 1:1060–1063, 1989.
Joklik WK: The molecular basis of the antiviral activity of interferons: Introductory remarks. Ann NY Acad Sci 350:432–440, 1980.
Schellekens H, Weimar W, Cantell K, Stitz L: Antiviral effect of interferon in vivo may be mediated by the host. Nature 278:742, 1979.
Murray HW: Interferon-γ, the activated macrophage, and host defense against microbial challenge. Ann Intern Med 108:595–608, 1988.
Arenzana-Seisdedos F, Virelizier JL, Fiers W: Interferons as macrophage-activating factors. III. Preferential effects of inter-feron-gamma on the interleukin 1 secretory potential of fresh or aged human monocytes. J Immunol 134:2444–2448, 1985.
Ennis FA, Meager A, Beare AS, et al: Interferon induction and increased natural killer-cell activity in influenza infections in man. Lancet 2:891–893, 1981.
Bryson YJ, Winter HS, Gard SE, Fischer TJ, Stiehm ER: Deficiency of immune interferon production by leukocytes of normal newborns. Cell Immunol 55:191–200, 1980.
Epstein LB, Ammann AJ: Evaluation of T lymphocyte effector function in immunodeficiency diseases: Abnormality in mitogen-stimulated interferon in patients with selective IgA deficiency. J Immunol 112:617–626, 1974.
Lipinski M, Virelizier JL, Tursz T, Griscelli C: Natural killer and killer cell activities in patients with primary immunodeficiencies or defects in immune interferon production. Eur J Immunol 10: 246–249, 1980.
Virelizier JL, Lenoir G, Griscelli C: Persistent Epstein-Barr virus infection in a child with hypergammaglobulinaemia and immuno-blastic proliferation associated with a selective defect in immune interferon secretion. Lancet 2:231–234, 1978.
Murray HW, Rubin BY, Masur H, Roberts RB: Impaired production of lymphokines and immune (gamma) interferon in the acquired immunodeficiency syndrome. N Engl J Med 310:883–889, 1984.
Buimovici-Klein E, Lange M, Ramey WG, Grieco MH, Cooper LZ: Cell-mediated immune responses in AIDS. N Engl J Med 311: 328–329, 1984.
Rossol S, Voth R, Laubenstein HP, et al: Interferon production in patients infected with HIV-1. J Infect Dis 159:815–821, 1989.
Rytel MW, Balay J: Impaired production of interferon in lymphocytes from immunosuppressed patients. J Infect Dis 127:445–449, 1973.
Weimar W, Van Ruyven CM, Geerlings W: Gamma interferon production capacily after renal transplantation. Transplant Proc 15:421–423, 1983.
Newport MJ, Huxley CM, Huston S, et al: A mutation in the interferon-gamma-receptor gene and susceptibility to mycobaclerial infection. N Engl J Med 335:1941–1949, 1996.
Dorman SE, Holland SM: Mutation in the signal-transducing chain of the interferon-gamma receptor and susceptibility to mycobaclerial infection. J Clin Invest 101:2364–2369, 1998.
Aarden L, Brunner TK, Cerotini JC: Revised nomenclature for antigen-non-specific T cell proliferation and helper factors. J Immunol 123:2928–2929, 1979.
Dinarello CA: Interleukin-1. FASEB J 2:108–115, 1988.
Beutler B, Cerami A: Cachectin: More than a tumor necrosis factor. N Engl J Med 316:379–385, 1987.
Van der Meer JWM, Barza M, Wolff SM, Dinarello CA: A low dose of recombinant interleukin 1 protects granulocytopenic mice from lethal gram-negative infection. Proc Natl Acad Sci USA 85:1620–1623, 1988.
Kindler V, Sappino AP, Grau GE, Piguet PF, Vassali P: The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 56:731–740, 1989.
Netea MG, Van Tits LHJ, Curfs JAHJ, et al: Increased susceplibilily of TNFaLTa double knockout mice to systemic candidiasis through impaired recruitment of neutrophils and phagocytosis of Candida albicans. J Immunol 163:1498–1505, 1999.
Waage A, Brandtzaeg P, Halstensen A, Kierulf P, Espevik T: The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin 6, interleukin 1, and fatal outcome. J Exp Med 169:333–338, 1989.
Cannon JG, Thompkins RG, Gelfand JA, et al: Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever. J Infect Dis 161:79–84, 1990.
Okusawa S, Gelfand JA, Gkejima T, Connolly RJ, Dinarello CA: Interleukin-1 induces a shock-like stale in rabbits. J Clin Invest 81:1162–1172, 1988.
Grau GE, Taylor TE, Molyneux ME, et al: Tumor necrosis factor and disease severity in children with falciparum malaria. N Engl J Med 320:1586–1591, 1989.
Mier JW, Vachino G, van der Meer JW, et al: Induction of circulating tumor necrosis factor (TNF alpha) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patients. J Clin Immunol 8:426–436, 1988.
Kuziel WA, Greene WC: Interleukin-2. In Thomson A (ed): The Cytokine Handbook. Academic Press, San Diego, 1991, pp. 83–102.
Rosenberg SA, Lotze MT, Muul LM, et al: A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med 316:889–897, 1987.
Schrader JW: Interleukin-3. In Thomson A (ed): The Cytokine Handbook. Academic Press, San Diego, 1991, pp. 103–118.
Banchereau J: Interleukin-4. In Thomson A (ed): The Cytokine Handbook. Academic Press, San Diego, 1991, pp. 119–148.
Carter KC, Gallagher G, Baillie AJ, Alexander J: The induction of protective immunity to Leishmania major in the BALB/c mouse by interleukin 4 treatment. Eur J Immunol 19:779–782, 1989.
Sanderson CJ: Interleukin-5. In Thomson A (ed): The Cytokine Handbook. Academic Press, San Diego, 1991, pp. 149–167.
Van Snick J: Interleukin-6: An overview. Annu Rev Immunol 8: 253–278, 1990.
Gauldie J, Richards C, Harnish D, Lansdorp P, Baumann H: Interferon beta 2/B-cell stimulatory factor type 2 shares identity with monocyte-derived hepatocyte-stimulating factor and regulates the major acute phase protein response in liver cells. Proc Natl Acad Sci USA 84:7251–7255, 1987.
Schindler R, Mancilla J. Endres S, Ghorbani R, Clark SC, Dinarello CA: Correlations and interactions in the production of interleukin-6 (IL-6), IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF. Blood 75:40–47, 1990.
Goodwin RG, Namen AE: Interleukin-7. In Thomson A (ed): The Cytokine Handbook. Academic Press, San Diego, 1991, pp. 192–200.
Van Damme J: Interleukin-8. In Thomson A (ed): The Cytokine Handbook. Academic Press, San Diego, 1991, pp. 201–214.
Renauld JC, Goethals A, Houssiau F, Merz H, Van Roost E, Van Snick J: Human P40/IL-9. Expression in activated CD4+ T cells, genomic organization, and comparison with the mouse gene. J Immunol 144:4235–4241, 1990.
Donahue RE, Yang YC, Clark SC: Human P40 T-cell growth factor (interleukin-9) supports erythroid colony formation. Blood 75:2271–2275, 1990.
Williams DE, Morrissey PJ, Mochizuki DY, et al: T-cell growth factor P40 promotes the proliferation of myeloid cell lines and enhances erythroid burst formation by normal murine bone marrow cells in vitro. Blood 76:906–911, 1990.
Zlotnik A, Moore KW: Interleukin 10. Cytokine 3:366–371, 1991.
Opal SM, Jhung JW, Keith JC Jr, et al: Recombinant human interleukin-11 in experimental Pseudomonas aeruginosa sepsis in immunocompromised animals. J Infect Dis 178:1205–1208, 1998.
Lamont AG, Adorini L: IL-12: A key cytokine in immune regulation. Immunol Today 17:214–217, 1996.
De Jong R, Altare F, Haagen IA, et al: Severe mycobacterial and Salmonella infections in interleukin-12 receptor-deficient patients. Science 280:1435–1438, 1998.
Altare F, Durandy A, Lammas D, et al: Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency. Science 280:1432–1435, 1998.
Chomarat P, Banchereau J: Interleukin-4 and interleukin-13: Their similarities and discrepancies. Int Rev Immunol 17:1–52, 1998.
Ambrus JL Jr. Pippin J, Joseph A, et al: Identification of a cDNA for a human high-molecular-weight B-cell growth factor [published erratum appears in Proc Natl Acad Sci USA 93(15):8154, 1996]. Proc Natl Acad Sci USA 90:6330–6334, 1993.
Trentin L, Zambello R, Facco M, Sancetta R, Agostini C, Semenzato G: Interleukin-15: A novel cytokine with regulatory properties on normal and neoplastic B lymphocytes. Leuk Lymphoma 27:35–42, 1997.
Waldmann TA, Tagaya Y: The multifaceted regulation of interleukin-15 expression and the role of this cytokine in NK cell differentiation and host response to intracellular pathogens. Annu Rev Immunol 17:19–49, 1999.
Cruikshank WW, Kornfeld H, Center DM: Signaling and functional properties of interleukin-16. Int Rev Immunol 16:523–540, 1998.
Center DM, Kornfeld H, Cruikshank WW: Interleukin 16 and its function as a CD4 ligand. Immunol Today 17:476–481, 1996.
Fossiez F, Banchereau J, Murray R, Van Kooten C, Garrone P, Lebecque S: Interleukin-17. Int Rev Immunol 16:541–551, 1998.
Dinarello CA: IL-18: A THl-inducing, proinflammatory cytokine and new member of the IL-1 family. J Allergy Clin Immunol 103: 11–24, 1999.
Fantuzzi G, Reed DA, Dinarello CA: IL-12-induced IFN-gamma is dependent on caspase-1 processing of the IL-18 precursor. J Clin Invest 104:761–767, 1999.
Puren AJ, Fantuzzi G, Gu Y, Su MS, Dinarello CA: Interleukin-18 (IFNγ-inducing factor)induces IL-8 and IL-1γvia TNFαproduction from non-CD14+ human blood mononuclear cells. J Clin Invest 101:711–721, 1998.
Groopman JE, Molina JM, Scadden DT: Hematopoietic growth factors. Biology and clinical applications. N Engl J Med 321: 1449–1459, 1989.
Moore MA: The clinical use of colony stimulating factors. Annu Rev Immunol 9:159–191, 1991.
Baldwin GC, Gasson JC, Quan SG, et al: Granulocyte-macrophage colony-stimulating factor enhances neutrophil function in acquired immunodeficiency syndrome patients. Proc Natl Acad Sci USA 85:2763–2766, 1988.
Roilides E, Walsh TJ, Pizzo PA, Rubin M: Granulocyte colony-stimulating factor enhances the phagocytic and bactericidal activity of normal and defective human neutrophils. J Infect Dis 163: 579–583, 1991.
Nathan CF: Respiratory burst in adherent human neutrophils: Triggering by colony-stimulating factors CSF-GM and CSF-G. Blood 73:301–306, 1989.
Dale DC, Bonilla MA, Davis MW, et al: A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severe chronic neutropenia. Blood 81:2496–2502, 1993.
Dignani MC, Anaissie EJ, Hester JP, et al: Treatment of neutro-penia-related fungal infections with granulocyte colony-stimulating factor-elicited white blood cell transfusions: A pilot study. Leukemia 11:1621–1630, 1997.
Nelson S, Belknap SM, Carlson RW, et al: A randomized controlled trial of filgrastim as an adjunct to antibiotics for treatment of hospitalized patients with community-acquired pneumonia. J Infect Dis 178:1075–1080, 1998.
Kullberg BJ, Vandewoude K, Herbrecht R, Jacobs F, Aoun M, Kujath P: A double-blind, randomized, placebo-controlled phase II study of filgrastim (recombinant granulocyte colony-stimulating factor) in combination with fluconazole for treatment of invasive candidiasis and candidemia in nonneutropenic patients. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, 1998, p. 479.
Görgen I, Hartung T, Leist M, et al: Granulocyte colony-stimulating factor treatment protects rodents against lipopolysaccharide-induced toxicity via suppression of systemic tumor necrosis factor-α. J Immunol 149:918–924, 1992.
Ikejima T, Okusawa S, Ghezzi P, Van der Meer JWM, Dinarello CA: Interleukin-1 induces tumor necrosis factor (TNF) in human peripheral blood mononuclear cells in vitro and a circulating TNF-like activity in rabbits. J Infect Dis 162:215–223, 1990.
Dinarello CA: Interleukin-1 and interleukin-1 antagonism. Blood 77:1627–1652, 1991.
Engelmann H, Novick D, Wallach D: Two tumor necrosis factor-binding proteins purified from human urine. Evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors. J Biol Chem 265:1531–1536, 1990.
Chantry D, Turner M, Abney E, Feldmann M: Modulation of cytokine production by transforming growth factor-beta. J Immunol 142:4295–4300, 1989.
Wakabayashi G, Gelfand JG, Burke JF, Thompson RC, Dinarello CA: A specific receptor antagonist for interleukin-1 prevents E. coli-induced shock in rabbits. FASEB J 5:338–343, 1991.
Dinarello CA, Thompson RC: Blocking IL-1—Interleukin-1 receptor antagonist in vivo and in vitro. Immunol Today 12:404–410, 1991.
Lesslauer W, Tabuchi H, Gentz R, et al: Recombinant soluble tumor necrosis factor proteins protect mice from lipopolysaccharide-induced lethality. Eur J Immunol 21:2883–2886, 1991.
Mohler KM, Torrance DS, Smith CA, et al: Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists. J Immunol 151:1548–1561, 1993.
Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL: Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 136:2348–2357, 1986.
Abbas AK, Murphy KM, Sher A: Functional diversity of helper T lymphocytes. Nature 383:787–793, 1996.
Romagnani S: Lymphokine production by human T cells in disease states. Annu Rev Immunol 12:227–257, 1994.
Kelso A: Thl and Th2 subsets: Paradigms lost? Immunol Today 16: 374–379, 1995.
Allen JE, Maizels RM: Thl-Th2: Reliable paradigm or dangerous dogma? Immunol Today 18:387–392, 1997.
Tonegawa S: Somatic generation of antibody diversity. Nature 302:575–581, 1983.
Oxelius VA: Chronic infections in a family with hereditary deficiency of IgG2 and IgG4. Clin Exp Immunol 17:19–27, 1974.
Siber GR, Schur PH, Aisenberg AC, Weitzman SA, Schiffman G: Correlation between serum IgG-2 concentrations and the antibody response to bacterial polysaccharide antigens. N Engl J Med 303: 178–182, 1980.
Tomasi TB Jr, Plaut AG: Humoral aspects of mucosal immunity. In Gallin JI, Fauci AS (eds): Advances in Host Defense Mechanisms. Raven Press, New York, 1982, pp. 31–61.
Andre C, Andre F, Fargier C: Distribution of IgA 1 and IgA 2 plasma cells in various normal human tissues and in the jejunum of plasma IgA-deficient patients. Clin Exp Immunol 33:327–331, 1978.
Buckley RH, Becker WG: Abnormalities in the regulation of human IgE synthesis. Immunol Rev 41:288–314, 1978.
Dessaint JP, Capron A, Joseph M: Interaction of schistosomiasis and macrophages. In Van Furth R (ed): Mononuclear Phagocytes: Characteristics, Physiology, and Function. Martinus Nijhoff, The Hague, 1985, pp. 593–598.
Vadas MA, Butterworth AE, Sherry B, et al: Interactions between human eosinophils and schistosomula of Schistosoma mansoni. I. Stable and irreversible antibody-dependent adherence. J Immunol 124:1441–1448, 1980.
Thorbecke GJ, Leski AA: Immunoglobulin D: Structure and function. Ann NY Acad Sci 399:1–410, 1982.
Rosen FS, Cooper MD, Wedgwood RJ: The primary immunodeficiencies (1). N Engl J Med 311:235–242, 1984.
Melamed I, Bujanover Y, Igra YS, Schwartz D, Zakuth V, Spirer Z: Campylobacter enteritis in normal and immunodeficient children. Am J Dis Child 137:752–753, 1983.
van der Meer JW, Mouton RP, Daha MR, Schuurman RK: Campylobacter jejuni bacteraemia as a cause of recurrent fever in a patient with hypogammaglobulinaemia. J Infect 12:235–239, 1986.
Ochs HD, Ament ME, Davis SD: Giardiasis with malabsorption in X-linked agammaglobulinemia. N Engl J Med 287:341–342, 1972.
Wright PF, Hatch MH, Kasselberg AG, Lowry SP, Wadlington WB, Karzon DT: Vaccine-associated poliomyelitis in a child with sex-linked agammaglobulinemia. J Pediatr 91:408–412, 1977.
McKinney RE Jr, Katz SL, Wilfert CM: Chronic enteroviral meningoencephalitis in agammaglobulinemic patients. Rev Infect Dis 9:334–356, 1987.
Saulsbury FT, Winkelstein JA, Yolken RH: Chronic rotavirus infection in immunodeficiency. J Pediatr 97:61–65, 1980.
So AK, Furr PM, Taylor-Robinson D, Webster AD: Arthritis caused by Mycoplasma salivarium in hypogammaglobulinaemia. Br Med J 286:762–763, 1983.
Taylor-Robinson D, Furr PM, Webster AD: Ureaplasma urealyticum in the immunocompromised host. Pediatr Infect Dis 5:S236–S238, 1986.
Ammann AJ, Hong R: Selective IgA deficiency: Presentation of 30 cases and a review of the literature. Medicine 50:223–236, 1971.
Oxelius VA, Laurell AB, Lindquist B, et al: IgG subclasses in selective IgA deficiency: Importance of IgG2-IgA deficiency. N Engl J Med 304:1476–1477, 1981.
Hobbs JR, Milner RD, Watt PJ: Gamma-M deficiency predisposing to meningococcal septicaemia. Br Med J 4:583–586, 1967.
Lefranc MP, Lefranc G, de Lange G, et al: Instability of the human immunoglobulin heavy chain constant region locus indicated by different inherited chromosomal deletions. Mol Biol Med 1:207–217, 1983.
Saffran DC, Parolini O, Fitch-Hilgenberg ME, et al: Brief report: A point mutation in the SH2 domain of Bruton’s tyrosine kinase in atypical X-linked agammaglobulinemia. N Engl J Med 330:1488–1491, 1994.
Reinherz EL, Geha R, Wohl ME, Morimoto C, Rosen FS, Schlossman SF: Immunodeficiency associated with loss of T4+ inducer T-cell function. N Engl J Med 304:811–816, 1981.
Eibl MM, Mannhalter JW, Zlabinger G, et al: Defective macrophage function in a patient with common variable immunodeficiency. N Engl J Med 307:803–806, 1982.
Van Kooten C, Banchereau J: CD40-CD40 ligand: A multifunctional receptor-ligand pair. Adv Immunol 61:1–77, 1996.
Kroczek RA, Graf D, Brugnoni D, et al: Defective expression of CD40 ligand on T cells causes “X-linked immunodeficiency with hyper-IgM (HIGM1)”. Immunol Rev 138:39–59, 1994.
Najjar VA, Fridkin M: Antineoplastic, immunogenic and other effects of the tetrapeptide tuftsin: A natural macrophage activator. Ann NY Acad Sci 419:1–273, 1983.
Corazza GR, Zoli G, Ginaldi L, et al: Tuftsin deficiency in AIDS. Lancet 337:12–13, 1991.
Opdenakker G, Fibbe WE, Van Damme J: The molecular basis of leukocytosis. Immunol Today 19:182–189, 1998.
Cronkite EP, Fliedner TM: Granulocytopoiesis. N Engl J Med 270:1347–1352, 1964.
Joyce RA, Boggs DR, Hasiba U, Srodes CH: Marginal neutrophil pool size in normal subjects and neutropenic patients as measured by epinephrine infusion. J Lab Clin Med 88:614–620, 1976.
Gallin JI, Wright DG, Malech HL, Davis JM, Klempner MS, Kirkpatrick CH: Disorders of phagocyte chemotaxis. Ann Intern Med 92:520–538, 1980.
Butcher EC: Leukocyte-endothelial cell recognition: Three (or more) steps to specificity and diversity. Cell 67:1033–1036, 1991.
Springer TA: Traffic signals for lymphocyte recirculation and leukocyte emigration: The multistep paradigm. Cell 76:301–314, 1994.
Hogg N: The leukocyte integrins. Immunol Today 10:111–114, 1989.
Arnaout MA, Hakim RM, Todd RFd, Dana N, Colten HR: Increased expression of an adhesion-promoting surface glycoprotein in the granulocytopenia of hemodialysis. N Engl J Med 312:457–462, 1985.
Bass DA: Eosinophil behavior during host defense reactions. In Gallin JI, Fauci AS (eds): Advances in Host Defense Mechanisms. Raven Press, New York, 1982, pp. 211–241.
Weller PF: The immunobiology of eosinophils. N Engl J Med 324:1110–1118, 1991.
Capron M, Desreumaux P: Immunobiology of eosinophils in allergy and inflammation. Res Immunol 148:29–33, 1997.
Simon HU, Yousefi S, Schranz C, Schapowal A, Bachert C, Blaser K: Direct demonstration of delayed eosinophil apoptosis as a mechanism causing tissue eosinophilia. J Immunol 158: 3902–3908, 1997.
Simon HU, Plotz SG, Dummer R, Blaser K: Abnormal clones of T cells producing interleukin-5 in idiopathic eosinophilia. N Engl J Med 341:1112–1120, 1999.
Van Furth R, Diesselhoff-Den Dulk MMC, Sluiter W: New perspectives on the kinetics of mononuclear phagocytes. In Van Furth R (ed): Mononuclear Phagocytes: Characteristics, Physiology, and Function. Martinus Nijhoff, The Hague, 1985, pp. 201–208.
Goud TJ, Schotte C, van Furth R: Identification and characterization of the monoblast in mononuclear phagocyte colonies grown in vitro. J Exp Med 142:1180–1199, 1975.
van der Meer JW, van de Gevel JS, Beelen RH, Fluitsma D, Hoefsmit EC, van Furth R: Culture of human bone marrow in the Teflon culture bag: Identification of the human monoblast. J Reticuloendothel Soc 32:355–369, 1982.
van Furth R, Raeburn JA, van Zwet TL: Characteristics of human mononuclear phagocytes. Blood 54:485–500, 1979.
Van Furth R: Cells of the mononuclear phagocyte system: Nomenclature in terms of sites and conditions. In Van Furth R (ed): Mononuclear Phagocytes: Functional Aspects. Martinus Nijhoff, The Hague, 1980, pp. 1–30.
Burger EH, Van der Meer JW, van de Gevel JS, Gribnau JC, Thesingh GW, van Furth R: In vitro formation of osteoclasts from long-term cultures of bone marrow mononuclear phagocytes. J Exp Med 156:1604–1614, 1982.
Snyderman R, Goetzl EJ: Molecular and cellular mechanisms of leukocyte chemotaxis. Science 213:830–837, 1981.
Sluiter W, Van Waarde D, Hulsing-Hesselink E: Humoral control of monocyte production during inflammation. In Van Furth R (ed): Mononuclear Phagocytes: Functional Aspects. Martinus Nijhoff, The Hague, 1980, pp. 325–339.
Chernoff AE, Granowitz EV, Shapiro L, et al: A randomized, controlled trial of IL-10 in humans. Inhibition of inflammatory cytokine production and immune responses. J Immunol 154:5492–5499, 1995.
Griffin FM Jr, Griffin JA, Leider JE, Silverstein SC: Studies on the mechanism of phagocytosis. I. Requirements for circumferential attachment of particle-bound ligands to specific receptors on the macrophage plasma membrane. J Exp Med 142:1263–1282, 1975.
Leijh PC, van den Barselaar MT, van Furth R: Kinetics of phagocytosis and intracellular killing of Staphylococcus aureus and Escherichia coli by human monocytes. Scand J Immunol 13:159–174, 1981.
Clark RA: The human neutrophil respiratory burst oxidase. J Infect Dis 161:1140–1147, 1990.
Wright DG: The neutrophil as a secretous organ of host defense. In Gallin JI, Fauci AS (eds): Advances in Host Defense Mechanisms. Raven Press, New York, 1982, pp. 75–110.
Lehrer RI, Ganz T: Antimicrobial polypeptides of human neutrophils. Blood 76:2169–2181, 1990.
Moncada S, Higgs EA: Endogenous nitric oxide: Physiology, pathology and clinical relevance. Eur J Clin Invest 21:361–374, 1991.
Vazquez-Torres A, Balish E: Macrophages in resistance to can-didiasis. Microbiol Mol Biol Rev 61:170–192, 1997.
Vazquez-Torres A, Jones-Carson J, Balish E: Peroxynitrite contributes to the candidacidal activity of nitric oxide-producing macrophages. Infect Immun 64:3127–3133, 1996.
Arend WP, Mannik M: Studies on antigen-antibody complexes. II. Quantification of tissue uptake of soluble complexes in normal and complement-depleted rabbits. J Immunol 107:63–75, 1971.
Van Es LA, Daha MR, Kijlstra A: Clearance of soluble immune complexes and aggregates. In Peeters H (ed): Protides of the Biological Fluids. Pergamon Press, Oxford, 1979, pp. 159–162.
Haakenstad AO, Mannik M: Saturation of the reticuloendothelial system with soluble immune complexes. J Immunol 112:1939–1948, 1974.
Atkinson JP, Frank MM: Studies on the in vivo effects of antibody. Interaction of IgM antibody and complement in the immune clearance and destruction of erythrocytes in man. J Clin Invest 54:339–348, 1974.
Nathan CF: Secretory products of macrophages. J Clin Invest 79:319–326, 1987.
Unanue ER: Antigen-presenting function of the macrophage. Anna Rev Immunol 2:395–428, 1984.
Unanue ER, Allen PM: The basis for the immunoregulatory role of macrophages and other accessory cells. Science 236:551–557, 1987.
Bodey GP, Buckley M, Sathe YS, Freireich EJ: Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 64:328–340, 1966.
van der Meer JW, Alleman M, Boekhout M: Infectious episodes in severely granulocytopenic patients. Infection 7:171–175, 1979.
Dale DC, Guerry Dt, Wewerka JR, Bull JM, Chusid MJ: Chronic neutropenia. Medicine 58:128–144, 1979.
Anderson DC, Schmalsteig FC, Finegold MJ, et al: The severe and moderate phenotypes of heritable Mac-1, LFA-1 deficiency: Their quantitative definition and relation to leukocyte dysfunction and clinical features. J Infect Dis 152:668–689, 1985.
Etzioni A, Frydman M, Pollack S, et al: Brief report: Recurrent severe infections caused by a novel leukocyte adhesion deficiency. N Engl J Med 327:1789–1792, 1992.
Miles AA, Miles EM, Burke J: The value and duration of defense reactions of the skin to the primary lodgment of bacteria. Br J Exp Pathol 38:79–96, 1957.
Frank MM, Hamburger MI, Lawley TJ, Kimberly RP, Plotz PH: Defective reticuloendothelial system Fc-receptor function in systemic lupus erythematosus. N Engl J Med 300:518–523, 1979.
Lobatto S, Daha MR, Breedveld FC, et al: Abnormal clearance of soluble aggregates of human immunoglobulin G in patients with systemic lupus erythematosus. Clin Exp Immunol 72:55–59, 1988.
Hamburger MI, Moutsopoulos HM, Lawley TJ, Frank MM: Sjögren’s syndrome: A defect in reticuloendothelial system Fcreceptor-specific clearance. Ann Intern Med 91:534–538, 1979.
Hamburger MI, Gerardi EN, Fields TR, Bennett RS: Lympho-plasmapheresis and reticuloendothelial system Fc receptor function in rheumatoid arthritis. Arthritis Rheum 24:S399–S404 1981.
Kimberly RP, Inman RD, Bussel JB, Polk JR, Hilgartner MW: Modulation of mononuclear phagocyte system function and circulating immune complexes by lyophilized concentrates in patients with classic hemophilia. Clin Immunol Immunopathol 31:321–330, 1984.
Ruiz P, Gomez F, Schreiber AD: Impaired function of macrophage Fc gamma receptors in end-stage renal disease. N Engl J Med 322:717–722, 1990.
Bender BS, Frank MM, Lawley TJ, Smith WJ, Brickman CM, Quinn TC: Defective reticuloendothelial system Fc-receptor function in patients with acquired immunodeficiency syndrome. J Infect Dis 152:409–412, 1985.
Lawley TJ, Hall RP, Fauci AS, Katz SI, Hamburger MI, Frank M: Defective Fc-receptor functions associated with the HLA-B8/DRw3 haplotype: Studies in patients with dermatitis herpetiforrmis and normal subjects. N Engl J Med 304:185–192, 1981.
Kimberly RP, Gibofsky A, Salmon JE, Fotino M: Impaired fcmediated mononuclear phagocyte system clearance in HLA-DR2 and MTl-positive healthy young adults. J Exp Med 157:1698–1703, 1983.
Jaffe CJ, Vierling JM, Jones EA, Lawley TJ, Frank MM: Receptor specific clearance by the reticuloendothelial system in chronic liver diseases. Demonstration of defective C3b-specific clearance in primary biliary cirrhosis. J Clin Invest 62:1069–1077, 1978.
Biozzi G, Benacerraf B, Halpern BN: Exploration of the phagocyte function of the reticuloendothelial system with heat denatured human serum albumin labeled with 1-131 and applications to the measurement of liver blood flow in normal man and in some pathological conditions. J Lab Clin Med 51:230–238, 1958.
Lahnborg G, Friman L, Berghem L: Reticuloendothelial function in patients with alcoholic liver cirrhosis. Scand J Gastroenterol 16:481–489, 1981.
Rimola A, Soto R, Bory F, Arroyo V, Piera C, Rodes J: Reticuloendothelial system phagocytic activity in cirrhosis and its relation to bacterial infections and prognosis. Hepatology 4:53–58, 1984.
Seidner DL, Mascioli EA, Istfan NW, et al: Effects of long-chain triglyceride emulsions on reticuloendothelial systemfunction in humans. J Parenter Enteral Nutr 13:614–619, 1989.
Dwyer JM: Manipulating the immune system with immune globulin. N Engl J Med 326:107–116, 1992.
Halma C, Daha MR, van der Meer JW, et al: Effect of monomeric immunoglobulin G (IgG) on the clearance of soluble aggregates of IgG in man. J Clin Lab Immunol 35:9–15, 1991.
Herberman RB: Natural killer cells. Annu Rev Med 37:347–352, 1986.
Krahenbuhl O, Tschopp J: The mechanism of lymphocyte-mediated killing. Perforin-induced pore formation. Immunol Today 12:399–402, 1991.
Ritz J: The role of natural killer cells in immune surveillance. N Engl J Med 320:1748–1749, 1989.
Biron CA, Byron KS, Sullivan JL: Severe herpesvirus infections in an adolescent without natural killer cells. N Engl J Med 320:1731–1735, 1989.
Lane HC, Fauci AS: Immunologic abnormalities in the acquired immunodeficiency syndrome. Annu Rev Immunol 3:477–500, 1985.
Van Voorhis WC, Valinsky J, Hoffman E, Luban J, Hair LS, Steinman RM: Relative efficacy of human monocytes and dendritic cells as accessory cells for T cell replication. J Exp Med 158:174–191, 1983.
Stingl G, Katz SI, Clement L, Green I, Shevach EM: Immunologic functions of Ia-bearingepidermal Langerhans cells. J Immunol 121:2005–2013, 1978.
Locksley RM: Interleukin-12 in host defense against microbial pathogens. Proc Natl Acad Sci USA 90:5879–5880, 1993.
Ballieux RE, Heijnen CJ: Immunoregulatory T cell subpopulations in man: Dissection by monoclonal antibodies and Fcreceptors. Immunol Rev 74:5–28, 1983.
Meuer SC, Schlossman SF, Reinherz EL: Clonal analysis of human cytotoxic T lymphocytes: T4+ and T8+ effector T cells recognize products of different major histocompatibility complex regions. Proc Natl Acad Sci USA 79:4395–4399, 1982.
Thomas Y, Rogozinski L, Irigoyen OH, et al: Functional analysis of human T cell subsets defined by monoclonal antibodies. IV. Induction of suppressor cells within the OKT4 + population. J Exp Med 154:459–467, 1981.
Hahn H, Kaufmann SH: The role of cell-mediated immunity in bacterial infections. Rev Infect Dis 3:1221–1250, 1981.
Murray HW: How protozoa evade intracellular killin. Ann Intern Med 98:1016–1018, 1983.
Bermudez LE, Young LS: Tumornecrosisfactor, alone or in combination with IL-2, but not IFN-γ is associated with macrophage killing of Mycobacterium avium complex. J Immunol 140 3006–3013, 1988.
Adams DO, Hamilton TA: The cell biology of macrophage activation. Annu Rev Immunol 2:283–318, 1984.
Siegel RL, Issekutz T, Schwaber J, Rosen FS, Geha RS: Deficiency of T helper cells in transient hypogammaglobulinemia of infancy. N Engl J Med 305:1307–1313, 1981.
Notarangelo LD: Immunodeficiencies caused by genetic defects in protein kinases. Curr Opin Immunol 8:448–453, 1996.
Itoh N, Yonehara S, Ishii A, et al: The polypeptide encoded by the cDNA for human cell surface antigen Fas can mediate apoptosis. Cell 66:233–243, 1991.
Smith CA, Farrah T, Goodwin RG: The TNF receptor superfamily of cellular and viral proteins: Activation, costimulation, and death. Cell 76:959–962, 1994.
Holland SM, Dorman SE, Kwon A, et al: Abnormal regulation of interferon-gamma, interleukin-12, and tumor necrosis factor-alpha in human interferon-gamma receptor 1 deficiency. J Infect Dis 178 1095–1104, 1998.
Hunninghake GW, Crystal RG: Pulmonary sarcoidosis: A disorder mediated by excess helper T-lymphocyte activity at sites of disease activity. N Engl J Med 305:429–434, 1981.
Rosen FS, Wedgwood RJP, Eibl M, et al: aPrimary immunodeficient diseases. Report of a WHO scientific group. Clin Exp linmunol 112(Suppl l):1–28, 1998.
Kallenberg CGM, Torensma R, The TH: The immune response to primary immunogens in man. In Reeves WG (ed): Recent Developments in Clinical Immunology. Elsevier, Amsterdam, 1984, pp. 1–26.
Weinberg ED: Pregnancy-associated depression of cell-mediated immunity. Rev Infect Dis 6:814–831, 1984.
Styrt B, Sugarman B: Estrogens and infection. Rev Infect Dis 13:1139–1150, 1991.
Skamene E (ed): Genetic Control of Host Response to Infection and Malignancy. Alan Liss, New York, 1985.
Hill AV: The immunogenetics of human infectious diseases. Annu Rev Immunol 16:593–617, 1998.
van Eden W, de Vries RR, van Rood JJ: The genetic approach to infectious disease, with special emphasis on the MHC. Disease Markers 1:221–242, 1983.
de Vries RR, Meera Khan P, Bernini LF, van Loghem E, van Rood JJ: Genetic control of survival in epidemics. J Immunogenet 6:271–287, 1979.
Hill AV, Allsopp CE, Kwiatkowski D, et al: Common west African HLA antigens are associated with protection from severe malaria. Nature 352:595–600, 1991.
Mira JP, Cariou A, Grail F, et al: Association of TNF2, a TNF-alpha promoter polymorphism, with septic shocksusceptibility and mortality: A multicenter study. JAMA 282:561–568, 1999.
Westendorp RG, Langermans JA, Huizinga TW, et al: Genetic influence on cytokine production and fatal meningococcal disease. Lancet n349:170–173, 1997.
de Vries RR, Ottenhoff TH, van Schooten WC: Human leukocyte antigens (HLA) and mycobacterial disease. Springer Semin Immunopathol 10:305–318, 1988.
Bellamy R, Ruwende C, Corrah T, McAdam KP, Whittle HC, Hill AV: Variations in the NRAMP1 gene and susceptibility to tuberculosis in West Africans. N Engl J Med 338:640–644, 1998.
Bellamy R, Ruwende C, Corrah T, et al: Tuberculosis and chronic hepatitis B virus infection in Africans and variation in the vitamin D receptor gene. J Infect Dis 179:721–724, 1999.
Pollack MS, Rich RR: The HLA complex and the pathogenesis of infectious diseases. J Infect Dis 151:1–8, 1985.
Chandra RK: Nutrition, immunity, and infection: Present knowledge and future directions. Lancet 1:688–691, 1983.
Keusch GT, Wilson CS, Waksal S: Nutrition, host defenses and the lymphoid system. In Gallin JI, Fauci AS (eds): Advances in Host Defense Mechanisms, Vol. 2. Raven Press, New York, 1983, pp. 275–359.
Salimonu LS, Ojo-Amaize E, Williams Al, et al: Depressed natural killer cell activity in children with protein-calorie malnutrition. Clin Immunol Immunopathol 24:1–7, 1982.
Sommer A, Tarwotjo I. Djunaedi E, et al: Impact of vitamin A supplementation on childhood mortality. A randomised controlled community trial. Lancet 1:1169–1173, 1986.
Hussey GD, Klein M: A randomized, controlled trial of vitamin A in children with severe measles. N Engl J Med 323:160–164, 1990.
Rahmathullah L, Underwood BA, Thulasiraj RD, et al: Reduced mortality among children in southern India receiving a small weekly dose of vitamin A. N Engl J Med 323:929–935, 1990.
West CE, Rombout JH, van der Zijpp AJ, Sijtsma SR: Vitamin A and immune function. Proc Nutr Soc 50:251–262, 1991.
Sugarman B: Zinc and infection. Rev Infect Dis 5:137–147, 1983.
Tucker SB, Schroeter AL, Brown PW Jr, McCall JT: Acquired zinc deficiency. Cutaneous manifestations typical of acroder-matitis enteropathica. JAMA 235:2399–2402, 1976.
Bullen JJ, Griffiths E (eds): Iron and Infection. John Wiley, New York, 1987.
Chandra RK, Au B, Woodford G. Hyam P: Iron status, immune response and susceptibility to infection. Ciba Found Symp 249–268, 1976.
Murray MJ, Murray AB, Murray MB, Murray CJ: The adverse effect of iron repletion on the course of certain infections. Br Med J 2:1113–1115, 1978.
van Asbeck BS, Verbrugh HA, van Oost BA, Marx JJ, Imhof HW, Verhoef J: Listeria monocytogenes meningitis and decreased phagocytosis associated with iron overload. Br Med J (Clin Res Ed) 284:542–544, 1982.
Boelaert JR, van Landuyt HW, Valcke YJ, et al: The role of iron overload in Yersinia enterocolitica and Yersinia pseudotuberculosis bacteremia in hemodialysis patients. J Infect Dis 156:384–387, 1987.
Craddock PR, Yawata Y, VanSanten L, Gilberstadt S, Silvis S, Jacob HS: Acquired phagocyte dysfunction. A complication of the hypophosphatemia of parenteral hyperalimentation. N Engl J Med 290:1403–1407, 1974.
Freeman J, Goldmann DA, Smith NE, Sidebottom DG, Epstein MF, Platt R: Association of intravenous lipid emulsion and coagulase-negative staphylococcal bacteremia in neonatal intensive care units. N Engl J Med 323:301–308, 1990.
Long JG, Keyserling HL: Catheter-related infection in infants due to an unusual lipophilic yeast-Malassezia furfur. Pediatrics 76:896–900, 1985.
Robin AP, Arain I, Phuangsab A, Holian O, Roccaforte P, Barrett JA: Intravenous fat emulsion acutely suppresses neutrophil chemiluminescence. J Parenter Enteral Nutr 13:608–613, 1989.
Netea MG, Curfs JHAJ, Demacker PMN, Meis JFGM, Van der Meer JWM, Kullberg BJ: Infusion of lipoproteins into human volunteers enhances the growth of Candida albicans. Clin Infect Dis 28:1148–1151, 1999.
Smith DH, Peter G, Ingram DL, Harding AL, Anderson P: Responses of children immunized with the capsular polysaccharide of Hemophilus influenzae, type b. Pediatrics 52:637–644, 1973.
Adamkin D, Stitzel A, Urmson J, Farnett ML, Post E, Spitzer R: Activity of the alternative pathway of complement in the newborn infant. J Pediatr 93:604–608, 1978.
Marodi L, Leijh PC, Braat A, Daha MR, van Furth R: Opsonic activity of cord blood sera against various species of microorganism. Pediatr Res 9:433–436, 1985.
Park BH, Holmes B, Good RA: Metabolic activities in leukocytes of newborn infants. J Pediatr 76:237–241, 1970.
McCracken GH Jr, Eichenwald HF: Leukocyte function and the development of opsonic and complement activity in the neonate. Am J Dis Child 121:120–126, 1971.
Schuit KE, Powell DA: Phagocytic dysfunction in monocytes of normal newborn infants. Pediatrics 65:501–504, 1980.
Marodi L, Leijh PC, van Furth R: Characteristics and functional capacities of human cord blood granulocytes and monocytes. Pediatr Res 18:1127–1131, 1984.
Marodi L, Jezerniczky J, Csorba S, Karmazsin L, Leijh PC, van Furth R: Chemotactic and random movement of cord-blood granulocytes. Experientia 40:1407–1410, 1984.
Marodi L, Csorba S, Nagy B: Chemotactic and random movement of human newborn monocytes. Eur J Pediatr 135:73–75, 1980.
van Tol MJ, Zijlstra J, Thomas CM, Zegers BJ, Ballieux RE: Distinct role of neonatal and adult monocytes in the regulation of the in vitro antigen-induced plaque-forming cell response in man. J Immunol 133:1902–1908, 1984.
Kohl S, Frazier JJ, Greenberg SB, Pickering LK, Loo LS: Interferon induction of natural killer cytotoxicity in human neonates. J Pediatr 98:379–384, 1981.
Wakasugi N, Virelizier JL: Defective IFN-gamma production in the human neonate. I. Dysregulation rather than intrinsic abnormality. J Immunol 134:167–171, 1985.
Phair J, Kauffman CA, Bjornson A, Adams L, Linnemann C Jr: Failure to respond to influenza vaccine in the aged: Correlation with B-cell number and function. J Lab Clin Med 92:822–828, 1978.
Roberts-Thomson IC, Whittingham S, Youngchaiyud U, Mackay IR: Ageing, immune response, and mortality. Lancet 2:368–370, 1974.
Wiedermann CJ, Niedermuhlbichler M, Beimpold H, Braunsteiner H: In vitro activation of neutrophils of the aged by recombinant human growth hormone. J Infect Dis 164:1017–1020, 1991.
Gardner ID: The effect of aging on susceptibility to infection. Rev Infect Dis 2:801–810, 1980.
Saltzman RL, Peterson PK: Immunodeficiency of the elderly. Rev Infect Dis 9:1127–1139, 1987.
Mackowiak PA: Direct effects of hyperthermia on pathogenic microorganisms: Teleologic implications with regard to fever. Rev Infect Dis 3:508–520, 1981.
Jampel HD, Duff GW, Gershon RK, Atkins E, Durum SK: Fever and immunoregulation. III. Hyperthermia augments the primary in vitro humoral immune response. J Exp Med 157:1229–1238, 1983.
Hanson DF, Murphy PA, Silicano R, Shin HS: The effect of temperature on the activation of thymocytes by interleukins I and II. J Immunol 130:216–221, 1983.
Dinarello CA, Dempsey RA, Allegretta M, et al: Inhibitory effects of elevated temperature on human cytokine production and natural killer activity. Cancer Res 6:6236–6241, 1986.
Roberts NJ Jr.: Impact of temperature elevation on immunologic defenses. Rev Infect Dis 13:462–472, 1991.
Shavit Y, Lewis JW, Terman GW, Gale RP, Liebeskind JC: Opioid peptides mediate the suppressive effect of stress on natural killer cell cytotoxicity. Science 223:188–190, 1984.
Young RA: Stress proteins and immunology. Annu Rev Immunol 8:401–420, 1990.
Swartz MN: Stress and the common cold. N Engl J Med 325:654–656, 1991.
Ironson G, Wynings C, Schneiderman N, et al: Posttraumatic stress symptoms, intrusive thoughts, loss, and immune function after Hurricane Andrew [see comments]. Psychosom Med 59:128–141, 1997.
Kiecolt-Glaser JK, Marucha PT, Malarkey WB, Mercado AM, Glaser R: Slowing of wound healing by psychological stress [see comments]. Lancet 346:1194–1196, 1995.
Cohen S, Tyrrell DA, Smith AP: Psychological stress and susceptibility to the common cold. N Engl J Med 325:606–612, 1991.
van der Meer JW, Guiot HP, van den Broek PJ, van Furth R: Infections in bone marrow transplant recipients. Semin Hematol 21:123–140, 1984.
Witherspoon RP, Lum LG, Storb R: Immunologic reconstitution after human marrow grafting. Semin Hematol 21:2–10, 1984.
Weeks JC, Tierney MR, Weinstein MC: Cost effectiveness of prophylactic intravenous immune globulin in chronic lymphocytic leukemia. N Engl J Med 325:81–86, 1991.
Bennett C, Vardiman J, Golomb H: Disseminated atypical mycobacterial infection in patients with hairy cell leukemia. Am J Med 80:891–896, 1986.
Engleman EG, Benike CJ, Hoppe RT, Kaplan HS, Berberich FR: Autologous mixed lymphocyte reaction in patients with Hodgkin’s disease. Evidence for a T cell defect. J Clin Invest 66:149–158, 1980.
Ward PA, Berenberg JL: Defective regulation of inflammatory mediators in Hodgkin’s disease. Supernormal levels of chemotactic-factor inactivator. N Engl J Med 290:76–80, 1974.
Weitzman SA, Aisenberg AC, Siber GR, Smith DH: Impaired humoral immunity in treated Hodgkin’s disease. N Engl J Med 297:245–248, 1977.
Chilcote RR, Baehner RL, Hammond D: Septicemia and meningitis in children splenectomized for Hodgkin’s disease. N Engl J Med 295:798–800, 1976.
Weitzman S, Aisenberg AC: Fulminant sepsis after the successful treatment of Hodgkin’s disease. Am J Med 62:47–50, 1977.
Schwartz PE, Sterioff S, Mucha P, Melton LJd, Offord KP: Postsplenectomy sepsis and mortality in adults. JAMA 248:2279–2283, 1982.
Kullberg BJ, Westendorp RG, van’t Wout JW, Meinders AE: Purpura fulminans and symmetrical peripheral gangrene caused by Capnocytophaga canimorsus (formerly DF-2)septicemia—A complication of dog bite. Medicine 70:287–292, 1991.
Hosea SW, Brown EJ, Hamburger MI, Frank MM: Opsonic requirements for intravascular clearance after splenectomy. N Engl J Med 304:245–250, 1981.
Benner R, Hijmans W, Haaijman JJ: The bone marrow: The major source of serum immunoglobulins, but still a neglected site of antibody formation. Clin Exp Immunol 46:1–8, 1981.
Schumacher MJ: Serum immunoglobulin and transferrin levels after childhood splenectomy. Arch Dis Child 45:114–117, 1970.
Di Padova F, Durig M, Harder F, Di Padova C, Zanussi C: Impaired antipneumococcal antibody production in patients without spleens. Br Med J (Clin Res Ed) 290:14–16, 1985.
Amlot PL, Hayes AE: Impaired human antibody response to the thymus-independent antigen, DNP-Ficoll, after splenectomy. Implications for post-splenectomy infections. Lancet 1:1008–1011, 1985.
Carlisle HN, Saslaw S: Properdin levels in splenectomized persons. Proc Soc Exp Biol Med 102:150–155, 1959.
Broome CV, Facklam RR, Fraser DW: Pneumococcal disease after pneumococcal vaccination: An alternative method to estimate the efficacy of pneumococcal vaccine. N Engl J Med 303:549–552, 1980.
Konradsen HB, Rasmussen C, Ejstrud P, Hansen JB: Antibody levels against Streptococcus pneumoniae and Haemophilus influenzae type b in a population of splenectomized individuals with varying vaccination status. Epidemiol Infect 119:167–174, 1997.
Teare L, O’Riordan S: Is splenectomy another indication for Haemophilus influenzae type b vaccination? Lancet 340:1362, 1992.
Barret-Connor E: Infection and sickle cell anemia. In Allen JC (ed): Infection in the Compromised Host: Clinical Correlations and Therapeutic Approaches. Williams & Wilkins, Baltimore, 1981, pp. 107–120.
Ballester OF, Prasad AS: Anergy, zinc deficiency, and decreased nucleoside phosphorylase activity in patients with sickle cell anemia. Ann Intern Med 98:180–182, 1983.
Ammann AJ, Addiego J, Wara DW, Lubin B, Smith WB, Mentzer WC: Polyvalent pneumococcal-polysaccharide immunization of patients with sickle-cell anemia and patients with splenectomy. N Engl J Med 297:897–900, 1977.
Allen JC: The diabetic as a compromised host. In Allen JC (ed): Infection in the Compromised Host: Clinical Correlations and Therapeutic Approaches. Williams & Wilkins, Baltimore, 1981, pp. 229–270.
Rubin J, Yu VL: Malignant external otitis: Insights into pathogenesis, clinical manifestations, diagnosis, and therapy. Am J Med 85:391–398, 1988.
Kullberg BJ, Van der Meer JWM: Zygomycosis. In Armstrong D, Cohen J (eds): Infectious Diseases. Mosby, London, 1999, pp. 4.9.14–4.9.15.
Meyers BR, Wormser G, Hirschman SZ, Blitzer A: Rhinocerebral mucormycosis: Premortem diagnosis and therapy. Arch Intern Med 139:557–560, 1979.
Artis WM, Fountain JA, Delcher HK, Jones HE: A mechanism of susceptibility to mucormycosiss in diabetic ketoacidosis: Transferrin and iron availability. Diabetes 31:1109–1114, 1982.
Brayton RG, Stokes PE, Schwartz MS, Louria DB: Effect of alcohol and various diseases on leukocyte mobilization, phagocytosis and intracellular bacterial killing. N Engl J Med 282: 123–128, 1970.
Mowat A, Baum J: Chemotaxis of polymorphonuclear leukocytes from patients with diabetes mellitus. N Engl J Med 284:621–627, 1971.
Miller ME, Baker L: Leukocyte functions in juvenile diabetes mellitus: Humoral and cellular aspects. J Pediatr 81:979–982, 1972.
Hill HR, Augustine NH, Rallison ML, Santos JI: Defective monocyte chemotactic responses in diabetes mellitus. J Clin Immunol 3:70–77, 1983.
Sheldon WH, Bauer H: The development of the acute inflammatory response to experimental cutaneous mucormycosis in normal and diabetic rabbits. J Exp Med 110:845–859, 1959.
Bagdade JD, Root RK, Bulger RJ: Impaired leukocyte function in patients with poorly controlled diabetes. Diabetes 23:9–15, 1974.
Chernew I, Braude AI: Depression of phagocytosis by solutes in concentrations found in the kidney and urine. J Clin Invest 41:1945–1951, 1962.
Nolan CM, Beaty HN, Bagdade JD: Further characterization of the impaired bactericidal function of granulocytes in patients with poorly controlled diabetes. Diabetes 27:889–894, 1978.
Tan JS, Anderson JL, Watanakunakorn C, Phair JP: Neutrophil dysfunction in diabetes mellitus. J Lab Clin Med 85:26–33, 1975.
Berken A, Sherman AA: Reticuloendothelial system phagocytosis in diabetes mellitus. Diabetes 23:218–220, 1974.
MacCuish AC, Urbaniak SJ, Campbell CJ, Duncan LJ, Irvine WJ: Phytohemagglutinin transformation and circulating lymphocyte subpopulations in insulin-dependent diabetic patients. Diabetes 23:708–712, 1974.
Eliashiv A, Olumide F, Norton L, Eiseman B: Depression of cell-mediated immunity in diabetes. Arch Surg 113:1180–1183, 1978.
Mahmoud AA, Rodman HM, Mandel MA, Warren KS: Induced and spontaneous diabetes mellitus and suppression of cell-mediated immunologic responses. Granuloma formation, delayed dermal reactivity and allograft rejection. J Clin Invest 57:362–367, 1976.
Parry MF, Root RK, Metcalf JA, Delaney KK, Kaplow LS, Richar WJ: Myeloperoxidase deficiency: Prevalence and clinical significance. Ann Intern Med 95:293–301, 1981.
Cech P, Stalder H, Widmann JJ, Rohner A, Miescher PA: Leukocyte myeloperoxidase deficiency and diabetes mellitus associated with Candida albicans liver abscess. Am J Med 66:149–153, 1979.
Montgomerie JZ, Kalmanson GM, Guze LB: Renal failure and infection. Medicine 47:1–32, 1968.
Clarke IA, Ormrod DJ, Miller TE: Host immune status in uremia. V. Effect of uremia on resistance to bacterial infection. Kidney Int 24:66–73, 1983.
Perescenschi G, Zakouth V, Spirer Z, Aviram A: Leukocyte mobilization by epinephrine and hydrocortisone in patients with chronic renal failure. Experientia 33:1529–1530, 1977.
Perillie PE, Nolan JP, Finch SC: Studies of the resistance to infection in diabetes mellitus: Local exudative cellular response. Lab Clin Med 59:1008–1015, 1962.
Salant DJ, Glover AM, Anderson R, et al: Depressed neutrophil chemotaxis in patients with chronic renal failure and after renal transplantation. J Lab Clin Med 88:536–545, 1976.
Abrutyn E, Solomons NW, St. Clair L, MacGregor RR, Root RK: Granulocyte function in patients with chronic renal failure: Surface adherence, phagocytosis, and bactericidal activity in vitro. J Infect Dis 135:1–8, 1977.
Urbanitz D, Sieberth HG: Impaired phagocytic activity of human monocytes in respect to reduced antibacterial resistance in uremia. Clin Nephrol 4:13–17, 1975.
Nelson J, Ormrod DJ, Miller TE: Host immune status in uremia. IV. Phagocytosis and inflammatory response in vivo. Kidney Int 23:312–319, 1983.
Kirkpatrick CH, Wilson WEC, Talmage DW: Immunologic studies in human organ transplantation. I. Observation and characterization of suppressed cutaneous reactivity in uremia. J Exp Med 119:727–742, 1964.
Newberry WM, Sanford JP: Defective cellular immunity in renal failure: Depression of reactivity of lymphocytes to phytohemag-glutinin by renal failure serum. J Clin Invest 50:1262–1271, 1971.
Daniels JC, Sakai H, Remmers AR Jr, et al: In vitro reactivity of human lymphocytes in chronic uraemia: Analysis and interpretation. Clin Exp Immunol 8:213–227, 1971.
Miller TE, Stewart E: Host immune status in uraemia. I. Cell-mediated immune mechanisms. Clin Exp Immunol 41:115–122, 1980.
Stevens CE, Alter HJ, Taylor PE, Zang EA, Harley EJ, Szmuness W: Hepatitis B vaccine in patients receiving hemodialysis. Immunogenicity and efficacy. N Engl J Med 311:496–501, 1984.
Crosnier J, Jungers P, Courouce AM, et al: Randomised placebo-controlled trial of hepatitis B surface antigen vaccine in French haemodialysis units: II, Haemodialysis patients. Lancet 1:797–800, 1981.
Desmyter J, Colaert J, De Groote G, et al: Efficacy of heatinactivated hepatitis B vaccine in haemodialysis patients and staff. Double-blind placebo-controlled trial. Lancet 2:1323–1328, 1983.
Lelie PN, Reesink HW, de Jong-van Manen ST, Dees PJ, Reerink-Brongers EE: Immune response to a heat-inactivated hepatitis B vaccine in patients undergoing hemodialysis. Enhancement of the response by increasing the dose of hepatitis B surface antigen from 3 to 27 micrograms. Arch Intern Med 145:305–309, 1985.
Meuer SC, Dumann H, Meyer zum Buschenfelde KH, Kohler H: Low-dose interleukin-2 induces systemic immune responses against HBsAg in immunodeficient non-responders to hepatitis B vaccination. Lancet 1:15–18, 1989.
Ruddy MC, Rubin AL, Novogrodsky A, Stenzel KH: Decreased macrophage-mediated suppression of lymphocyte activation in chronic renal failure. Am J Med 75:571–579, 1983.
Sengar DP, Rashid A, Harris JE: In vitro reactivity of lymphocytes obtained from uraemic patients maintained by heamodialysis. Clin Exp Immunol 21:298–305, 1975.
Langhoff E, Ladefoged J: Cellular immunity in renal failure: Depression of lymphocyte transformation by uraemia and methylprednisolone. Intra-individual consistency of lymphocyte responses to the in vitro suppressive effect of steroid. Int Arch Allergy Appl Immunol 74:241–245, 1984.
Boelaert JR, Daneels RF, Schurgers ML, Matthys EG, Gordts BZ, Van Landuyt HW: Iron overload in haemodialysis patients increases the risk of bacteraemia: A prospective study. Nephrol Dial Transplant 5:130–134, 1990.
Boelaert JR, Vergauwe PL, Vandepitte JM: Mucormycosis infection in dialysis patients. Ann Intern Med 107:782–783, 1987.
De Locht M, Boelaert JR, Schneider YJ: Iron uptake from ferrioxamine and from ferrirhizoferrin by germinating spores of Rhizopus microsporus. Biochem Pharmacol 47:1843–1850, 1994.
Gloor HJ, Nichols WK, Sorkin MI, et al: Peritoneal access and related complications in continuous ambulatory peritoneal dialysis. Am J Med 74:593–598, 1983.
Verbrugh HA, Keane WF, Hoidal JR, Freiberg MR, Elliott GR, Peterson PK: Peritoneal macrophages and opsonins: Antibacterial defense in patients undergoing chronic peritoneal dialysis. J Infect Dis 147:1018–1029, 1983
Keane WF, Peterson PK: Host defense mechanisms of the peritoneal cavity and continuous ambulatory peritoneal dialysis. Peritoneal Dialysis Bull 4:122–127, 1984.
Amair P, Khanna R, Leibel B, et al: Continuous ambulatory peritoneal dialysis in diabetics with end-stage renal disease. N Engl J Med 306:625–630, 1982.
Gluckman SJ, Dvorak VC, MacGregor RR: Host defenses during prolonged alcohol consumption in a controlled environment. Arch Intern Med 137:1539–1543, 1977.
MacGregor RR, Spagnuolo PJ, Lentnek AL: Inhibition of granulocyte adherence by ethanol, prednisone, and aspirin, measured with an assay system. N Engl J Med 291:642–646, 1974.
MacGregor RR: Alcohol and immune defense. JAMA 256:1474–1479, 1986.
Bermudez LE, Young LS: Ethanol augments intracellular survival of Mycobacterium avium complex and impairs macrophage responses to cytokines. J Infect Dis 163:1286–1292, 1991.
Berenyi MR, Straus B, Cruz D: In vitro and in vivo studies of cellular immunity in alcoholic cirrhosis. Am J Dig Dis 19:199–205, 1974.
Saxena QB, Mezey E, Adler WH: Regulation of natural killer activity in vivo, II. The effect of alcohol consumption on human peripheral blood natural killer activity. Int J Cancer 26:413–417, 1980.
Wilcox CM, Dismukes WE: Spontaneous bacterial peritonitis. A review of pathogenesis, diagnosis, and treatment. Medicine 66: 447–456, 1987.
DeMeo AN, Andersen BR: Defective chemotaxis associated with a serum inhibitor in cirrhotic patients. N Engl J Med 286:735–740, 1972.
Blussé van Oud Alblas A, Janssens AR, Leijh PC, van Furth R: Functions of granulocytes and monocytes in primary biliary and alcoholic cirrhosis. Clin Exp Immunol 62:724–731, 1985.
Wyke RJ, Rajkovic IA, Williams R: Impaired opsonization by serum from patients with chronic liver disease. Clin Exp Immunol 51:91–98, 1983.
Runyon BA: Patients with deficient ascitic fluid opsonic activity are predisposed to spontaneous bacterial peritonitis [published erratum appears in Hepatology 8(5):1184, 1988]. Hepatology 8:632–635, 1988.
Sorrell MF, Leevy CM: Lymphocyte transformation and alcoholic liver injury. Gastroenterology 63:1020–1025, 1972.
Staples PJ, Gerding DN, Decker JL, Gordon RS Jr: Incidence of infection in systemic lupus erythematosus. Arthritis Rheum 17:1–10, 1974.
Abeles M: The rheumatic patient as a compromised host. In Allen JC (ed): Infection in the Compromised Host: Clinical Correlations and Therapeutic Approaches. Williams & Wilkins, Baltimore, 1981, pp. 197–227.
Ginzler E, Diamond H, Kaplan D, Weiner M, Schlesinger M, Seleznick M: Computer analysis of factors influencing frequency of infection in systemic lupus erythematosus. Arthritis Rheum 21:37–44, 1978.
Moutsopoulos HM, Gallagher JD, Decker JL, Steinberg AD: Herpes zoster in patients with systemic lupus erythematosus. Arthritis Rheum 21:789–802, 1978.
Clark RA, Kimball HR, Decker JL: Neutrophil chemotaxis in systemic lupus erythematosus. Ann Rheum Dis 33:167–172, 1974.
Perez HD, Lipton M, Goldstein IM: A specific inhibitor of complement (C5)-derived chemotactic activity in serum from patients with systemic lupus erythematosus. J Clin Invest 62:29–38,1978.
Jasin HE, Orozco JH, Ziff M: Serum heat labile opsonins in systemic lupus erythematosus. J Clin Invest 53:343–353, 1974.
Zurier RB: Reduction of phagocytosis and lysosomal enzyme release from human leukocytes by serum from patients with systemic lupus erythematosus. Arthritis Rheum 19:73–78, 1976.
Kimball HR, Wolff SM, Talal N, Plotz PH, Decker JL: Marrow granulocyte reserves in the rheumatic diseases. Arthritis Rheum 16:345–352, 1973.
Rosenthal CJ, Franklin EC: Depression of cellular-mediated immunity in systemic lupus erythematosus. Relation to disease activity. Arthritis Rheum 18:207–217, 1975.
Mowat AG, Baum J: Chemotaxis of polymorphonuclear leukocytes from patients with rheumatoid arthritis. J Clin Invest 50: 2541–2549, 1971.
Bar-Eli M, Ehrenfeld M, Litvin Y, Gallily R: Monocyte function in rheumatoid arthritis. Scand J Rheumatol 9:17–23, 1980.
Turner RA, Schumacher R, Myers AR: Phagocytic function of polymorphonuclear leukocytes in rheumatic diseases. J Clin Invest 52:1632–1635, 1973.
Breedveld FC, Fibbe WE, Hermans J, van der Meer JW, Cats A: Factors influencing the incidence of infections in Felty’s syndrome. Arch Intern Med 147:915–920, 1987.
Mackowiak PA: Microbial synergism in human infections. N Engl J Med 298:21–26, 1978.
O’Grady F, Smith H (eds): Microbial Perturbation of Host Defences. Academic Press, New York, 1981.
Solberg CO, Helium KB: Neutrophil granulocyte function in bacterial infections. Lancet 2:727–730, 1972.
Barbour AG, Allred CD, Solberg CO, Hill HR: Chemiluminescence by polymorphonuclear leukocytes from patients with active bacterial infection. J Infect Dis 141:14–26, 1980.
Parenti DM, Snydman DR: Capnocytophaga species: Infections in nonimmunocompromised and immunocompromised hosts. J Infect Dis 151:140–147, 1985.
Shurin SB, Socransky SS, Sweeney E, Stossel TP: A neutrophil disorder induced by capnocytophaga, a dental micro-organism. N Engl J Med 301:849–854, 1979.
Rubin RH, Cosimi AB, Tolkoff-Rubin NE, Russell PS, Hirsch MS: Infectious disease syndromes attributable to cytomegalovirus and their significance among renal transplant recipients. Transplantation 24:458–464, 1977.
Chatterjee SN, Fiala M, Weiner J, Stewart JA, Stacey B, Warmer N: Primary cytomegalovirus and opportunistic infections. Incidence in renal transplant recipients. JAMA 240:2446–2449, 1978.
Rand KH, Pollard RB, Merigan TC: Increased pulmonary super-infections in cardiac-transplant patients undergoing primary cytomegalovirus infection. N Engl J Med 98:951–953, 1978.
Carney WP, Rubin RH, Hoffman RA, Hansen WP, Healey K, Hirsch MS: Analysis of T lymphocyte subsets in cytomegalovirus mononucleosis. J Immunol 26:2114–2116, 1981.
Van Es A, van Gemert GW, Baldwin WK: Viral infection and T-lymphocyte subpopulations in renal transplant recipients. N Engl J Med 09:110–111, 1983.
LaQuaglia MP, Tolkoff-Rubin NE, Dienstag JL, et al: Impact of hepatitis on renal transplantation. Transplantation 32:504–507, 1981.
Singh N, Gayowski T, Wagener MM, Marino IR: Increased infections in liver transplant recipients with recurrent hepatitis C virus hepatitis. Transplantation 61:402–406, 1996.
Greene WC: The molecular biology of human immunodeficiency virus type 1 infection. N Engl J Med 324:308–317, 1991.
Smith PD, Ohura K, Masur H, Lane HC, Fauci AS, Wahl SM: Monocyte function in the acquired immune deficiency syndrome. Defective chemotaxis. J Clin Invest 74:2121–2128, 1984.
Schneider MM, Borleffs JC, Stolk RP, Jaspers CA, Hoepelman AI: Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1-infected patients treated with highly active antiretroviral therapy. Lancet 353:201–203, 1999.
Foudraine NA, Hovenkamp E, Notermans DW, et al: Immunopathology as a result of highly active antiretroviral therapy in HIV-1-infected patients. AIDS 13:177–184, 1999.
Berenguer J, Solera J, Diaz MD, Moreno S, Lopez-Herce JA, Bouza E: Listeriosis in patients infected with human immunodeficiency virus. Rev Infect Dis 13:115–119, 1991.
Sobel JD: Controversial aspects of candidiasis in the acquired immunodeficiency syndrome. In Vandenbossche H, Mackenzie D, Cauwenbergh G, Drouet E, Dupont B (eds): Mycoses in AIDS Patients. Plenum Press, New York, 1990, pp. 93–100.
Lazzarin A, Uberti Foppa C, Galli M, et al: Impairment of polymorphonuclear leucocyte function in patients with acquired immunodeficiency syndrome and with lymphadenopathy syndrome. Clin Exp Immunol 65:105–111, 1986.
Ellis M, Gupta S, Galant S, et al: Impaired neutrophil function in patients with AIDS or AIDS-related complex: A comprehensive evaluation. J Infect Dis 158:1268–1276, 1988.
Redd SC, Rutherford GWd, Sande MA, et al: The role of human immunodeficiency virus infection in pneumococcal bacteremia in San Francisco residents. J Infect Dis 162:1012–1017, 1990.
Schlamm HT, Yancovitz SR: Haemophilus influenzas pneumonia in young adults with AIDS, ARC, or risk of AIDS. Am J Med 86: 11–14, 1989.
Steinhoff MC, Auerbach BS, Nelson KE, et al: Antibody responses to Haemophilus influenzae type B vaccines in men with human immunodeficiency virus infection. N Engl J Med 325: 1837–1842, 1991.
Kroon FP, van Dissel JT, Rijkers GT, Labadie J, van Furth R: Antibody response to Haemophilus influenzae type b vaccine in relation to the number of CD4+ T lymphocytes in adults infected with human immunodeficiency virus. Clin Infect Dis 25:600–606, 1997.
Kroon FP, van Dissel JT, Ravensbergen E, Nibbering PH, van Furth R: Antibodies against pneumococcal polysaccharides after vaccination in HIV-infected individuals: 5-year follow-up of antibody concentrations. Vaccine 18:524–530, 1999.
Jacobson MA, Gellermann H, Chambers H: Staphylococcus aureus bacteremia and recurrent staphylococcal infection in patients with acquired immunodeficiency syndrome and AIDS-related complex. Am J Med 85:172–176, 1988.
Stevens DA, Denning DW: Pulmonary aspergillosis in AIDS. N Engl J Med 325:354–357, 1991.
Schaffner A: Pulmonaryaspergillosis in AIDS. N Engl J Med 325:354–357, 1991.
Denning DW, Follansbee SE, Scolaro M, Norris S, Edelstein H, Stevens DA: Pulmonary aspergillosis in the acquired immunodeficiency syndrome. N Engl J Med 324:654–662, 1991.
Graham BS, Tucker WS Jr: Opportunistic infections in endogenous Cushing’s syndrome. Ann Intern Med 101:334–338, 1984.
Fauci AS, Dale DC, Balow JE: Glucocorticosteroid therapy: Mechanisms of action and clinical considerations. Ann Intern Med 84:304–315, 1976.
Stuck AE, Minder CE, Frey FJ: Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis 11:954–963, 1989
Sneiderman CA, Wilson JW: Effects of corticosteroids on complement and the neutrophilic polymorphonuclear leukocyte. Transplant Proc 7:41–48, 1975.
Butler WT, Rossen RD: Effects of corticosteroids on immunity in man. I. Decreased serum IgG concentration caused by 3 or 5 days of high doses of methylprednisolone. J Clin Invest 52:2629–2640, 1973.
Suda T, Miura Y, Ijima H, Ozawa K, Motoyoshi K, Takaku F: The effect of hydrocortisone on human granulopoiesis in vitro with cytocheniical analysis of colonies. Exp Hematol 11:114–121,1983.
Dale DC, Fauci AS, Guerry DI, Wolff SM: Comparison of agents producing a neutrophilic leukocytosis in man. Hydrocortisone, prednisone, endotoxin, and etiocholanolone. J Clin Invest 56:808–813, 1975.
Dale DC, Fauci AS, Wolff SM: Alternate-day prednisone. Leukocyte kinetics and susceptibility to infections. N Engl J Med 291: 1154–1158, 1974.
Wiener SL, Wiener R, Urivetzky M, et al: The mechanism of action of a single dose of methylprednisolone on acute inflammation in vivo. J Clin Invest 56:679–689, 1975.
Thompson J, Furth Rv: The effect of glucocorticosteroids on the kinetics of mononuclear phagocytes. J Exp Med 131:429–442, 1970.
Rinehart JJ, Balcerzak SP, Sagone AL, LoBuglio AF: Effects of corticosteroids on human monocyte function, J Clin Invest 54: 1337–1343, 1974.
Rinehart JJ, Sagone AL, Balcerzak SP, Ackerman GA, LoBuglio AF: Effects of corticosteroid therapy on human monocyte function. N Engl J Med 292:236–241, 1975.
Van Zwet TL, Thompson J, Van Furth R: Effect of glucocorticosteroids on the phagocytosis and intracellular killing by peritoneal macrophages. Infect Immun 12:699–705, 1975.
Atkinson JP, Frank MM: Complement-independent clearance of IgG-sensitize erythrocytes: Inhibition by cortisone. Blood 44: 629–637, 1974
Werb ZA: Hormone receptors and hormonal regulation of macrophage physiological functions. In Van Furth R (ed): Mononuclear Phagocytes: Functional Aspects, Martinus Nijhoff, The Hague, 1980, pp. 809–829.
Knudsen PJ, Dinarello CA, Strom TB: Glucocorticoids inhibit transcriptional and posttranscriptional expression of interleukin 1 in U937 cells. J Immunol 139:4129–4134, 1987.
Luedke CE, Cerami A: Interferon-gamma overcomes glucocorticoid suppression of cachectin/tumor necrosis factor biosynthesis by murine macrophages. J Clin Invest 86:1234–1240, 1990.
Roilides E, Uhlig K, Venzon D, Pizzo PA, Walsh TJ: Prevention of corticosteroid-induced suppression of human polymorphonuclear leukocyte-induced damage of Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon. Infect Immun 61:4870–4877, 1993.
Dannenberg AM Jr: The antinflammatory effects of glucocorticosteroids. A brief review of the literature. Inflammation 3:329–343, 1979.
Cupps TR, Fauci AS: Corticosteroid-mediated immunoregulation in man. Immunol Rev 64:134–155, 1982.
Gustafson TL, Schaffner W, Lavely GB, Stratton CW, Johnson HK, Hutcheson RH Jr: Invasive aspergillosis in renal transplant recipients: Correlation with corticosteroid therapy. J Infect Dis 148:230–238, 1983.
Gershwin ME, Goetzl EJ, Steinberg AD: Cyclophosphamide: Use in practice. Ann Intern Med 80:531–540, 1974.
Balow JE: Cyclophosphamide suppression of established cell-mediated immunity. J Clin Invest 56:65–70, 1975.
Fauci AS, Wolff SM, Johnson JS: Effect of Cyclophosphamide upon the immune response in Wegener’s granulomatosis. N Engl J Med 285:1493–1496, 1971.
Ten Berge RJ, Schellekens PT: A critical analysis of the use of azathioprine in clinical medicine. Neth J Med 26:164–171, 1983.
Losito A, Williams DG, Cooke G, Harris L: The effects on polymorphonuclear leucocyte function of prednisolone and azathioprine in vivo and prednisolone, azathioprine and 6-mercaptopurine in vitro. Clin Exp Immunol 32:423–428, 1978.
Hersh EM, Wong VG, Freireich EJ: Inhibition of the local inflammatory response in man by antimetabolites. Blood 27:38–48, 1966.
Cseuz R, Panayi GS: The inhibition of NK cell function by azathioprine during the treatment of patients with rheumatoid arthritis. Br J Rheumatol 29:358–362, 1990.
Förre O, Bjerkhoel F, Salvesen CF, et al: An open, controlled, randomized comparison of cyclosporine and azathioprine in the treatment of rheumatoid arthritis: A preliminary report. Arthritis Rheum 30:88–92, 1987.
Andersen PA, West SG, O’Dell JR, Via CS, Claypool RG, Kotzin BL: Weekly pulse methotrexate in rheumatoid arthritis. Clinical and immunologic effects in a randomized, double-blind study. Ann Intern Med 103:489–496, 1985.
Boerbooms AM, Jeurissen ME, Westgeest AA, Theunisse H, Van de Putte LB: Methotrexate in refractory rheumatoid arthritis. Clin Rheumatol 7:249–256, 1988.
Hyams JS, Donaldson MH, Metcalf JA, Root RK: Inhibition of human granulocyte function by methotrexate. Cancer Res 38: 650–655, 1978.
Johnston CA, Russell AS, Kovithavongs T, Dasgupta M: Measures of immunologic and inflammatory responses in vitro in rheumatoid patients treated with methotrexate. J Rheumatol 13: 294–296, 1986.
Johnson WJ, DiMartino MJ, Meunier PC, Muirhead KA, Hanna N: Methotrexate inhibits macrophage activation as well as vascular and cellular inflammatory events in rat adjuvant induced arthritis. J Rheumatol 15:745–749, 1988.
Barrera P, Boerbooms AM, Demacker PN, van de Putte LB, Gallati H, van der Meer JW: Circulating concentrations and production of cytokines and soluble receptors in rheumatoid arthritis patients: Effects of a single dose methotrexate. Br J Rheumatol 33:1017–1024, 1994.
Kim JH, Perfect JR: Infection and cyclosporine. Rev Infect Dis 11:677–690, 1989.
Spencer CM, Goa KL, Gillis JC: Tacrolimus. An update of its pharmacology and clinical efficacy in the management of organ transplantation. Drugs 54:925–975, 1997.
Kalian BD: Cyclosporin. N Engl J Med 321:1725–1738, 1989.
Granelli-Piperno A, Inaba K, Steinman RM: Stimulation of lymphokine release from T lymphoblasts. Requirement for mRNA synthesis and inhibition by cyclosporin A. J Exp Med 160:1792–1802, 1984.
Shin GT, Khanna A, Ding R, et al: In vivo expression of transforming growth factor-betal in humans: Stimulation by cyclosporine. Transplantation 65:313–318, 1998.
European FK506 Multicentre Liver Study Group: Randomised trial comparing tacrolimus (FK506) and cyclosporin in prevention of liver allograft rejection. Lancet 344:423–428, 1994.
Jensik SC, and the FK 506 Kidney Transplant Study Group: Tacrolimus (FK 506) in kidney transplantation: Three-year survival results of the US multicenter, randomized, comparative trial. Transplant Proc 30:1216–1218, 1998.
Sievers TM, Rossi SJ, Ghobrial RM, et al: Mycophenolate mofetil. Pharmacotherapy 17:1178–1197, 1997.
The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group: A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. Transplantation 61:1029–1037, 1996.
US Renal Transplant Mycophenolate Mofetil Study Group: Mycophenolate mofetil in cadaveric renal transplantation. Am J Kidney Dis 34:296–303, 1999.
Moreso F, Seron D, Morales JM, et al: Incidence of leukopenia and cytomegalovirus disease in kidney transplants treated with mycophenolate mofetil combined with low cyclosporine and steroid doses. Clin Transplant 12:198–205, 1998.
Vincenti F, Kirkman R, Light S, et al: Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. N Engl J Med 338:161–165, 1998.
Vincenti F, Grinyo J, Ramos E, et al: Can antibody prophylaxis allow sparing of other immunosuppressives? Transplant Proc 31: 1246–1248, 1999.
Nashan B, Moore R, Amlot P, et al: Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. Lancet 350:1193–1198, 1997.
Kahan BD, Julian BA, Pescovitz MD, Vanrenterghem Y, Neylan J, Group atRS: Sirolimus reduces the incidence of acute rejection episodes despite lower cyclosporine doses in Caucasian recipients of mismatched primary renal allografts: A phase II trial. Transplantation 68:1526–1532, 1999.
Sayegh MH, Turka LA: The role of T-cell costimulatory activation pathways in transplant rejection. N Engl J Med 338:1813–1821, 1998.
Hauser WE, Remington JS: The effect of antibiotics on the humoral and cell-mediated immune responses. In Sabath LD (ed): Action of Antibiotics in Patients. Huber, Bern, 1982, pp. 127–147.
Morikawa K, Watabe H, Araake M, Morikawa S: Modulatory effect of antibiotics on cytokine production by human monocytes in vitro. Antimicrob Agents Chemother 40:1366–1370, 1996.
Bergeron Y, Deslauriers AM, Ouellet N, Gauthier MC, Bergeron MG: Influence of cefodizime on pulmonary inflammatory response to heat-killed Klebsiella pneumoniae in mice. Antimicrob Agents Chemother 43:2291–2294, 1999.
Riesbeck K, Sigvardsson M, Leanderson T, Forsgren A: Superinduction of cytokine gene transcription by ciprofloxacin. J Immunol 153:343–352, 1994.
Genovese F, Mancuso G, Cuzzola M, et al: Improved survival and antagonistic effect of sodium fusidate on tumor necrosis factor alpha in a neonatal mouse model of endotoxin shock. Antimicrob Agents Chemother 40:1733–1735, 1996.
Thomas MZ, Medoff G, Kobayashi GS: Changes in murine resistance to Listeria monocytogenes infection induced by amphotericin B. J Infect Dis 127:373–377, 1973.
Vonk AG, Netea MG, Denecker NEJ, Verschueren ICMM, Van der Meer JWM, Kullberg BJ: Modulation of the pro-and antiinflammatory cytokine balance by amphotericin B. J Antimicrobial Chemother 42:469–474, 1998.
Cosimi AB: The clinical value of antilymphocyte antibodies. Transplant Proc 13:462–468, 1981.
Thistlethwaite JR Jr, Stuart JK, Mayes JT, et al: Complications and monitoring of OKT3 therapy. Am J Kidney Dis 11:112–119, 1988.
Frenken LA, Hoitsma AJ, Tax WJ, Koene RA: Prophylactic use of anti-CD3 monoclonal antibody WT32 in kidney transplantation. Transplant Proc 23:1072–1073, 1991.
Burk ML, Matuszewski KA: Muromonab-CD3 and antithymocyte globulin in renal transplantation. Ann Pharmacother 31:1370–1377, 1997.
Rubin RH, Cosimi AB, Hirsch MS, Herrin JT, Russell PS, Tolkoff-Rubin NE: Effects of antithymocyte globulin on cytomegalovirus infection in renal transplant recipients. Transplantation 31:143–145, 1981.
Macris MP, Van Buren CT, Sweeney MS, Frazier OH, Duncan JM: Selective use of OKT3 in heart transplantation with the use of risk factor analysis. J Heart Transplant 8:296–302, 1989.
Gordon RD, Tzakis AG, Iwatsuki S, et al: Experience with Orthoclone OKT3 monoclonal antibody in liver transplantation. Am J Kidney Dis 11:141–144, 1988.
Renlund DG, O’Connell JB, Gilbert EM, et al: A prospective comparison of murine monoclonal CD-3 (OKT3) antibody-based and equine antithymocyte globulin-based rejection prophylaxis in cardiac transplantation. Decreased rejection and less corticosteroid use with OKT3. Transplantation 47:599–605, 1989.
Millis JM, McDiarmid SV, Hiatt JR, et al: Randomized prospective trial of OKT3 for early prophylaxis of rejection after liver transplantation. Transplantation 47:82–88, 1989.
Grino JM, Alsina J, Sabater R, et al: Antilymphoblast globulin, cyclosporine, and steroids in cadaveric renal transplantation. Transplantation 49:1114–1117, 1990.
van Rood JJ, Claas FH: The influence of allogeneic cells on the human T and B cell repertoire. Science 248:1388–1393, 1990.
Lagaaij EL, Hennemann IP, Ruigrok M, et al: Effect of one-HLA-DR-antigen-matched and completely HLA-DR-mismatched blood transfusions on survival of heart and kidney allografts. N Engl J Med 321:701–705, 1989.
Lederman MM, Ratnoff OD, Scillian JJ, Jones PK, Schacter B: Impaired cell-mediated immunity in patients with classic hemophilia. N Engl J Med 308:79–83, 1983.
Gascon P, Zoumbos NC, Young NS: Immunoiogic abnormalities in patients receiving multiple blood transfusions. Ann Intern Med 100:173–177, 1984.
Wing EJ, Bruns FJ, Fraley DS, Segel DP, Adler S: Infectious complications with plasmapheresis in rapidly progressive glomerulonephritis. JAMA 244:2423–2426, 1980.
Pohl MA, Lan SP, Berl T: Plasmapheresis does not increase the risk for infection in immunosuppressed patients with severe lupus nephritis. The Lupus Nephritis Collaborative Study Group. Ann Intern Med 114:924–929, 1991.
van Deuren M, Santman FW, van Dalen R, Sauerwein RW, Span LF, van der Meer JW: Plasma and whole blood exchange in meningococcal sepsis. Clin Infect Dis 15:424–430, 1992.
Van der Meer JWM, Van Deuren M, Kullberg BJ: The interplay of pro-inflammatorycytokinesandanti-inflammatorymediatorsduring severe infection. In Vincent JL (ed): Yearbook of Intensive Care and Emergency Medicine. Springer, Brussels, 1995, pp. 377–383.
van Deuren M, Frieling JT, van der Ven-Jongekrijg J, et al: Plasma patterns of tumor necrosis factor-alpha (TNF) and TNF soluble receptors during acute meningococcal infections and the effect of plasma exchange. Clin Infect Dis 26:918–923, 1998.
Doria G, Agarossi G, Adorini L: Selective effects of ionizing radiations on immunoregulatory cells. Immunol Rev 65:23–54, 1982.
Baehner RL, Neiburger RG, Johnson DE, Murrmann SM: Transient bactericidal defect of peripheral blood phagocytes from children with acute lymphoblastic leukemia receiving craniospinal irradiation. N Engl J Med 289:1209–1213, 1973.
Slater JM, Ngo E, Lau BH: Effect of therapeutic irradiation on the immune responses. Am J Roentgenol 126:313–320, 1976.
Strober S, Dhillon M, Schubert M, et al: Acquired immune tolerance to cadaveric renal allografts. A study of three patients treated with total lymphoid irradiation. N Engl J Med 321:28–33, 1989.
Eskola J, Kayhty H, Takala AK, et al: A randomized, prospective field trial of a conjugate vaccine in the protection of infants and young children against invasive Haemophilus influenzae type b disease. AC Engl J Med 323:1381–1387, 1990.
Brown GL, Nanney LB, Griffen J, et al: Enhancement of wound healing by topical treatment with epidermal growth factor. N Engl J Med 321:76–79, 1989.
Greenhalgh DG: The role of growth factors in wound healing. J Trauma 41:159–167, 1996.
Raz R, Stamm WE: A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. N Engl J Med 329:753–756, 1993.
Eriksen B: A randomized, open, parallel-group study on the preventive effect of an estradiol-releasing vaginal ring (Estring) on recurrent urinary tract infections in postmenopausal women. Am J Obstet Gynecol 180:1072–1079, 1999.
Reichman RC, Oakes D, Bonnez W, et al: Treatment of condyloma acuminatum with three different interferon-alpha preparations administered parenterally: A double-blind, placebo-controlled trial. J Infect Dis 162:1270–1276, 1990.
Perrillo RP, Schiff ER, Davis GL, et al: A randomized, controlled trial of interferon alfa-2b alone and after prednisone withdrawal for the treatment of chronic hepatitis B. The Hepatitis Interventional Therapy Group. N Engl J Med 323:295–301, 1990.
Wong DK, Cheung AM, O’Rourke K, Naylor CD, Detsky AS, Heathcote J: Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 119:312–323, 1993.
de Jongh FE, Janssen HL, de Man RA, Hop WC, Schalm SW, van Blankenstein M: Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 103:1630–1635, 1992.
Davis GL, Balart LA, Schiff ER, et al: Treatment of chronic hepatitis C with recombinant interferon alfa. A multicenter randomized, controlled trial. Hepatitis Interventional Therapy Group. N Engl J Med 321:1501–1506, 1989.
Davis GL, Esteban-Mur R, Rustgi V, et al: Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N Engl J Med 339:1493–1499, 1998.
Nathan CF, Kaplan G, Levis WR, et al: Local and systemic effects of intradermal recombinant interferon-gamma in patients with lepromatous leprosy. N Engl J Med 315:6–15, 1986.
Barral-Netto M, Santos S, Santos I, et al: Immunochemotherapy with interferon-gamma and multidrug therapy for multibacillary leprosy. Acta Trap 72:185–201, 1999.
Sampaio EP, Moreira AL, Sarno EN, Malta AM, Kaplan G: Prolonged treatment with recombinant interferon gamma induces erythema nodosum leprosum in lepromatous leprosy patients. J Exp Med 175:1729–1737, 1992.
Badaro R, Falcoff E, Badaro FS, et al: Treatment of visceral leishmaniasis with pentavalent antimony and interferon gamma. N Engl J Med 322:16–21, 1990.
Squires KE, Rosenkaimer F, Sherwood JA, Forni AL, Were JB, Murray HW: Immunochemotherapy for visceral leishmaniasis: A controlled pilot trial of antimony versus antimony plus interferongamma. Am J Trap Med Hyg 48:666–669, 1993.
Gallin JI, Malech HL, Melnick DA, and the International Chronic Granulomatous Disease Cooperative Study Group: A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. N Engl J Med 324:509–516, 1991.
Bernhisel-Broadbent J, Camargo EE, Jaffe HS, Lederman HM: Recombinant human interfcron-γ as adjunct therapy for Aspergillus infection in a patient with chronic granulomatous disease. J Infect Dis 163:908–911, 1991.
Rex JH, Bennett JE, Gallin JI, Malech HL, Decarlo ES, Melnick DA: In vivo interfcron-γ therapy augments the in vitro ability of chronic granulomatous disease neutrophils to damage Aspergillus hyphae. J Infect Dis 163:849–852, 1991.
Condos R, Rom WN, Schluger NW: Treatment of multidrugresistant pulmonary tuberculosis with interferon-gamma via aerosol. Lancet 349:1513–1515, 1997.
Holland SM, Eisenstein EM, Kuhns DB, et al: Treatment of refractory disseminated nontuberculous mycobacterial infection with interferon gamma. A preliminary report. N Engl J Med 330:1348–1355, 1994.
Kullberg BJ, Van’t Wout JW, Poelt RJM, Van Furth R: Combined effect of fluconazole and recombinant human interleukin-1 on systemic candidiasis in mice. Antimicrob Agents Chemother 36 1225–1229, 1992.
Vogels MTE, Van der Meer JWM: Use of immune modulators in nonspecific therapy of bacterial infections. Antimicrob Agents Chemother 36:1–5, 1992.
Doi S, Saiki O, Hara T, et al: Administration of recombinant IL-2 augments the level of serum IgM in an IL-2 deficient patient. Eur J Pediatr 148:630–633, 1989.
Pahwa R, Chatila T, Pahwa S, et al: Recombinant interleukin 2 therapy in severe combined immunodeficiency disease. Proc Natl Acad Sci USA 86:5069–5073, 1989.
Cohn ZA, Kaplan G: Hansen’s disease, cell-mediated immunity, and recombinant lymphokines. J Infect Dis 163:1195–1200, 1991.
Klempner MS, Noring R, Mier JW, Atkins MB: An acquired chemotactic defect in neutrophils from patients receiving interleukin-2 immunotherapy. N Engl J Med 322:959–965, 1990.
Crawford J, Ozer H, Stoller R, et al: Reduction by granulocyte colony-stimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 325:164–170, 1991.
Maher DW, Lieschke GJ, Green M, et al: Filgrastim in patients with chemotherapy-induced febrile neutropenia. A double-blind, placebo-controlled trial. Ann Intern Med 121:492–501, 1994.
Rowe JM, Andersen JW, Mazza JJ, et al: A randomized placebo-controlledphase III study of granulocyte-macrophage colonystimulating factor in adult patients (ã 55 to 70 years of age) with acute myelogenous leukemia: A study of the Eastern Cooperative Oncology Group (E1490). Blood 86:457–462, 1995.
Boxer LA, Hutchinson R, Emerson S: Recombinant human granulocyte-colony-stimulatingfactor in the treatment of patients with neutropenia. Clin Immunol Immunopathol 62:S39–S46, 1992.
Kullberg BJ, Netea MG, Curfs JHAJ, Keuter M, Meis JFGM, Van der Meer JWM: Recombinant murine granulocyte colonystimulating factor protects against acute disseminated Candida albicans infection in non-neutropenic mice. J Infect Dis 177:175–181, 1998.
Buckley RH, Schiff RI: The use of intravenous immune globulin in immunodeficiency diseases. N Engl J Med 325:110–117, 1991.
Van der Meer JWM, De Windt GE, Van den Broek PJ: Subcutaneous immunoglobulin substitution in hypogammaglobulinemia. In Krijnen HW, Strengers PFW, Van Aken WG (eds): Immunoglobulins. CLB, Amsterdam, 1988, pp. 71–76.
Gardulf A, Hammarstrom L, Smith CI: Home treatment of hypogammaglobulinaemia with subcutaneous gammaglobulin by rapid infusion. Lancet 338:162–166, 1991.
Winston DJ, Young LS: Immunization of the compromised host against infectious complications. In Allen JC (ed): Infection in the Compromised Host: Clinical Correlations and Therapeutic Approaches. Williams & Wilkins, Baltimore, 1981, pp. 37–89.
Winston DJ, Ho WG, Lin CH, et al: Intravenous immune globulin for prevention of cytomegalovirus infection and interstitial pneumonia after bone marrow transplantation. Ann Intern Med 106:12–18, 1987.
Reed EC, Bowden RA, Dandliker PS, Lilleby KE, Meyers JD: Treatment of cytomegalovirus pneumonia with ganciclovir and intravenous cytomegalovirus immunoglobulin in patients with bone marrow transplants. Ann Intern Med 109:783–788, 1988.
Emanuel D, Cunningham I, Jules-Elysee K, et al: Cytomegalovirus pneumonia after bone marrow transplantation successfully treated with the combination of ganciclovir and high-dose intravenous immune globulin. Ann Intern Med 109:777–782, 1988.
Sullivan KM, Kopecky KJ, Jocom J, et al: Immunomodulatory and antimicrobial efficacy of intravenous immunoglobulin in bone marrow transplantation. N Engl J Med 323:705–712, 1990.
Keusch GT, Ambinder EP, Kovacs I, Goldberg JD, Phillips DM, Holland JF: Role of opsonins in clinical response to granulocyte transfusion in granulocytopenic patients. Am J Med 73:552–563, 1982.
Norrby-Teglund A, Kaul R, Low DE, et al: Plasma from patients with severe invasive group A streptococcal infections treated with normal polyspecific IgG inhibits streptococcal superantigeninduced T cell proliferation and cytokine production. J Immunol 156:3057–3064, 1996.
Kaul R, McGeer A, Norrby-Teglund A, et al: Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome–A comparative observational study. Clin Infect Dis 28:800–807, 1999.
Groothuis JR, Simoes EA, Levin MJ, et al: Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group. N Engl J Med 329:1524–1530, 1993.
The prevent Study Group: Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics 99:93–99, 1997.
The IMpact-RSV Study Group: Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 102:531–537, 1998.
Ziegler EJ, Fisher CJ Jr, Sprung CL, et al: Treatment of gramnegative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. N Engl J Med 324:429–436, 1991.
Greenberg RN, Wilson KM, Kunz AY, Wedel NI, Gorelick KJ: Randomized, double-blind phase II study of anti-endotoxin antibody (E5) as adjuvant therapy in humans with serious gramnegative infections. Prog Clin Biol Res 367:179–186, 1991.
Derkx B, Wittes J, McCloskey R, and the Euroean Pediatric Meningococcal Septic Shock Trial Study Group: Randomized, placebo-controlled trial of HA-!A, a human monoclonal antibody to endotoxin, in children with meningococcalseptic shock. Clin Infect Dis 28:770–777, 1999.
Tracey KJ, Fong Y, Hesse DG, et al: Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia. Nature 330:662–664, 1987.
Fisher CJ Jr, Agosti JM, Opal SM, et al: Treatment of septic shock with the tumor necrosis factor recepton:Fc fusion protein. N Engl J Med 334:1697–1702, 1996.
Abraham E, Wunderink R, Silverman H, et al: Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. JAMA 273:934–941, 1995.
Opal SM, Fisher CJ Jr, Dhainaut JF, et al: Confirmatory interleukin-1 receptor antagonist trial in severe sepsis: A phase III, randomized, double-blind, placebo-controlled, multicenter trial. The Interleukin-1 Receptor Antagonist Sepsis Investigator Group. Crit Care Med 25:1115–1124, 1997.
Bone RC: Why sepsis trials fail. JAMA 276:565–566, 1996.
Zeni F, Freeman B, Natanson C: Anti-inflammatory therapies to treat sepsis and septic shock: A reassessment. Crit Care Med 25:1095–1100, 1997.
Elliott MJ, Maini RN, Feldmann M, et al: Randomised doubleblind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. Lancet 344:1105–1110, 1994.
Targan SR, Hanauer SB, Van Deventer SHJ, et al: A short-term study of chimeric monoclonal antibody Ca2 to tumor necrosis factor-α for Crohn’s disease. N Engl J Med 337:1029–1035, 1997.
Echtenacher B, Falk W, Mannel DN, Krammer PH: Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis. J Immunol 145:3762–3766, 1990.
Scharfman WB, Tillotson JR, Taft EG, Wright E: Plasmapheresis for meningococcemia with disseminated intravascular coagulation. N Engl J Med 300:1277–1278, 1979.
Bjorvatn B, Bjertnaes L, Fadnes HO, et al: Meningococcal septicaemia treated with combined plasmapheresis and leucapheresis or with blood exchange. Br Med J (Clin Res Ed) 288:439–441, 1984.
Winston DJ, Ho WG, Gale RP: Therapeutic granulocyte transfusions for documented infections. A controlled trial in ninety-five infectious granulocytopenic episodes. Ann Intern Med 97:509–515, 1982.
van der Meer JW, van den Broek PJ: Present status of the management of patients with defective phagocyte function. Rev Infect Dis 6:107–121, 1984.
Feldman E, Hester JP, Vartivarian SE. The use of granulocyte colony-stimulating factor-enhanced granulocyte transfusions from normal donors in patients with neutropenia-related fungal infections. 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC, 1993, Abstract 711.
Hassner A, Adelman DC: Biologic response modifiers in primary immunodeficiency disorders. Ann Intern Med 115:294–307, 1991.
Hershfield MS, Buckley RH, Greenberg ML, et al: Treatment of adenosine deaminase deficiency with polyethylene glycol-modified adenosine deaminase. N Engl J Med 316:589–596, 1987.
Hoogerbrugge PM, van Beusechem VW, Fischer A, et al: Bone marrow gene transfer in three patients with adenosine deaminase deficiency. Gene Ther 3:179–183, 1996.
Onodera M, Ariga T, Kawamura N, et al: Successful peripheral T-lymphocyte-directed gene transfer for a patient with severe combinedimmune deficiency caused by adenosine deaminase deficiency. Blood 91:30–36, 1998.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Kluwer Academic Publishers
About this chapter
Cite this chapter
van der Meer, J.W.M., Kullberg, B.J. (2002). Defects in Host Defense Mechanisms. In: Rubin, R.H., Young, L.S., Van Furth, R. (eds) Clinical Approach to Infection in the Compromised Host. Springer, Boston, MA. https://doi.org/10.1007/0-306-47527-8_2
Download citation
DOI: https://doi.org/10.1007/0-306-47527-8_2
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-306-46693-9
Online ISBN: 978-0-306-47527-6
eBook Packages: Springer Book Archive